

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification: C12Q 1/68, C12M 1/36, C12P 19/34	A1	(11) International Publication Number: WO 00/79006 (43) International Publication Date: 28 December 2000 (28.12.2000)
(21) International Application Number: PCT/US00/16722 (22) International Filing Date: 16 June 2000 (16.06.2000) (30) Priority Data: 60/139,843 17 June 1999 (17.06.1999) US (60) Parent Application or Grant FRED HUTCHINSON CANCER RESEARCH CENTER [/]; (). UNIVERSITY OF WASHINGTON [/]; (). PETERSDORF, Ellie, W. [/]; (). GUO, Zhen [/]; (). HANSEN, John, A. [/]; (). HOOD, Leroy [/]; (). PETERSDORF, Ellie, W. [/]; (). GUO, Zhen [/]; (). HANSEN, John, A. [/]; (). HOOD, Leroy [/]; (). KEZER, William, B. ; ().		Published
(54) Title: OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING (54) Titre: RESEAUX OLIGONUCLEOTIDIQUES DESTINES AU TYPAGE DE HLA HAUTE RESOLUTION (57) Abstract Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus. (57) Abrégé L'invention concerne des réseaux de sondes oligonucléotidiques HLA classe I sur support solide, lesdites sondes étant suffisantes pour représenter au moins 80 % des polymorphismes connus dans les exons 2 et 3 du locus de HLA classe I.		

ATTORNEY DOCKET NUMBER: 9301-094
SERIAL NUMBER: 09/781,814
REFERENCE: BV

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
28 December 2000 (28.12.2000)

PCT

(10) International Publication Number
WO 00/79006 A1

- (51) International Patent Classification⁷: C12Q 1/68,
C12P 19/34, C12M 1/36
- (21) International Application Number: PCT/US00/16722
- (22) International Filing Date: 16 June 2000 (16.06.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/139,843 17 June 1999 (17.06.1999) US
- (71) Applicants (*for all designated States except US*): FRED HUTCHINSON CANCER RESEARCH CENTER [US/US]; 1100 Fairview Avenue North, M/S C2M 027, Seattle, WA 98109-1024 (US). UNIVERSITY OF WASHINGTON [US/US]; Office Of Technology Transfer, 1107 N.E. 45th Street, Suite 200, Seattle, WA 98105 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): PETERSDORF, Effie, W. [US/US]; 3716 47th Place NE, Seattle, WA 98105 (US). GUO, Zhen [US/US]; 14611 N.E. 39th Apt. 1044, Bellevue, WA 98007 (US). HANSEN, John, A. [US/US]; 9103 S.E. 78th Place, Mercer Island, Wa 98040 (US). HOOD, Leroy [US/US]; 6411 Windermere Road, Seattle, WA 98105 (US).
- (74) Agents: KEZER, William, B. et al.; Townsend and Townsend and Crew, LLP, Two Embarcadero Center, 8th Floor, San Francisco, CA 94111 (US).
- (81) Designated States (*national*): AU, CA, JP, US.
- (84) Designated States (*regional*): European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 00/79006 A1

(54) Title: OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING

(57) Abstract: Arrays of HLA Class I oligonucleotide probes on a solid support are provided, wherein the probes are sufficient to represent at least 80% of the known polymorphisms in exons 2 and 3 of the HLA Class I locus.

Description

5

10

15

20

25

30

35

40

45

50

55

OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING

CROSS-REFERENCES TO RELATED APPLICATIONS

This application claims the benefit of United States Provisional Patent
Application Serial No. 60/139,843, filed on June 17, 1999.

STATEMENT AS TO RIGHTS TO INVENTIONS MADE UNDER FEDERALLY SPONSORED RESEARCH AND DEVELOPMENT

The U.S. government may have certain rights in the invention pursuant to
Grant No. CA 18029, R01 HG01713-02 and 98-3300-416457 received from the U.S.
National Institutes of Health.

FIELD OF THE INVENTION

This invention relates to arrays of oligonucleotides that are useful for HLA
typing. The arrays are specifically designed and constructed to facilitate diagnostic
evaluations and assist in phenotypic analysis for such uses as donor/recipient transplant
compatibility.

BACKGROUND OF THE INVENTION

Oligonucleotide array technology is a revolutionary tool in modern molecular
biology. The combination of a standard nucleic acid hybridization approach with innovative
high-density DNA array technology has proven to be a powerful method for high-throughput
DNA sequence analysis. Initially developed to improve sequencing efforts in the Human
Genome Project, the oligonucleotide array technology has been successfully applied to many
fields of molecular biology, including large scale gene discovery, monitoring the expression
of thousands of genes, mutation and polymorphism detection, as well as mapping of
genomic clones.

Oligonucleotide arrays are manufactured either by in situ combinatorial
oligonucleotide synthesis or by conventional synthesis followed by on-chip immobilization
of the oligonucleotide onto the solid support. Sample DNA is amplified by the polymerase
chain reaction (PCR), labeled with a fluorescent tag and hybridized to the oligonucleotide

array. The hybridization pattern is measured by fluorescence scanning and the intensity of each hybridization signal is quantified using a "spot-finding" software.

Oligonucleotide arrays provide the ability to assay many different combinations of DNA sequences simultaneously. Oligonucleotide arrays have been applied to study diverse and complex genetic systems. The utility of array technology for the detection of new mutations and polymorphisms, gene discovery, gene expression and mapping has been convincingly demonstrated (Pease et al., *Proc. Natl. Acad. Sci. USA* 91:5022-5026 (1994); Wodicka et al., *Nature Biotech.*, 15:1359-1367 (1997); Hacia et al., *Nature Genetics* 18:155-158 (1998); Sapolsky and Lipshutz, *Genomics* 33: 445-456 (1996)). However, an efficient HLA array has not yet been produced.

Thus while the innovative high-density oligonucleotide array technology has proven to be a powerful method for high-through-put DNA sequence analysis, a practical system to systematically identify all alleles of any HLA gene has never been developed.

The human major histocompatibility genes are among the most polymorphic genes known in the human genome. HLA antigens are encoded by a series of closely linked genes located at the position p21 on chromosome 6. Genes of the HLA region span approximately 4 million bases of DNA, and are clustered into three distinct regions designated class I, class II and class III. Genes within the class I and class II regions share structural and functional properties and are considered to be part of the immunoglobulin gene super family. Although distinct in sequence and structure, both class I and class II genes encode proteins that are critical in controlling T-cell recognition and determining histocompatibility in marrow transplantation (Rammensee, *Curr. Opin. Immunol.* 7:85-96 (1995)).

At least 17 loci including several pseudogenes exist in the HLA class I region. Three of these loci encode HLA-A, -B and -C alloantigens that constitute the major class I determinants important for matching in tissue transplantation. The HLA-A, -B and -C loci show a striking degree of sequence and structural homology with one another and genes at all three loci are highly polymorphic (Bodmer et al., *Tissue Antigens* 49:297-321 (1997)). Currently, more than 86 HLA-A, 185 HLA-B and 45 HLA-C alleles have been described. More recently, three additional class I genes, HLA-E, -F and -G, have been defined (Geraghty et al., *J. Exp. Med.* 171:1-19; 53, 54 (1990); Geraghty et al., *Proc. Natl. Acad. Sci. USA* 84:9145-49, 54 (1987); Koller et al., *J. Immunol.* 141:897-904 (1988)). Although HLA-E, -F and -G genes are structurally homologous with HLA-A, B and C

genes, they appear to have limited polymorphism, the tissue expression of their encoded molecules is more restricted, and their potential role as transplantation antigens is unknown.

The HLA class II region is comprised of nine distinct genes: DRA, DRB1, DRB3, DRB4, DRB5, DQA, DQB, DPA and DPB. Six additional class II genes or gene fragments have been described but these are either nonfunctional pseudogenes or do not encode proteins known to participate in transplant-related immune interactions. Class II genes are divided into five families, designated DR, DQ, DO, DN and DP, based on their degree of sequence homology and their location within the HLA-D region. As with class I genes, class II DR, DQ and DP genes show a striking degree of polymorphism, with more than 220 alleles thus far defined at the DRB1 locus (Bodmer et al., *supra*, (1997)).

The identification of HLA alleles has significance in both medical clinics and genetic research. Detection of HLA polymorphisms and their frequencies in population is the key to study the fundamental issues in immunogenetics, such as evolutionary diversification of HLA system and the linkage between certain HLA types and disease susceptibility.

The clinical importance of the identification of HLA polymorphisms can be illustrated by its application in marrow transplantation. Matching of HLA allele types of patients and those of donors has proven essential for the success of unrelated marrow transplantation for hematologic malignancies. Current standards for HLA typing include serological methods for HLA-A, -B and -C antigens and DNA-based typing for class II HLA-DRB1 and DQB1 alleles. DNA-based methods remain the most accurate when compared to serological methods. The optimization of the outcome of unrelated marrow transplantation thus requires the comprehensive analysis of both HLA class I and class II genes of transplant populations.

The limiting factor in large-scale genetic analysis of transplant populations has been methodologic and directly involves the technical ability to accurately define the alleles of highly polymorphic HLA genes in a cost-effective and efficient manner. Although recent progress in the development of traditional probe hybridization and sequencing-based methods has allowed alleles to be determined with accuracy, large-scale efforts in genetic analysis of transplant populations are hampered by the cost of available methods, particularly for the highly polymorphic HLA-A, -B and -C genes.

There therefore exists a need in the art for methods for the identification of all alleles of any HLA gene. This invention addressed these needs by providing methods and compositions for the systematic identification HLA alleles and for HLA typing.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides an array of HLA Class I oligonucleotide probes on a solid support, wherein the probes are sufficient to represent at least 80% of the known polymorphisms of the HLA Class I locus. Preferably, the probes represent at least 90%, and more preferably at least 98% of the known polymorphisms of the HLA Class I locus. Particularly preferred probes are those that represent the known polymorphisms of exons 2 and 3 of the HLA Class I locus. Typically the oligonucleotide probes will comprise from about 17 to 23 nucleic acid residues, with those having about 20 nucleic acid residues being preferred. Additionally, the HLA Class I oligonucleotide probes are preferably HLA-A oligonucleotide probes, HLA-B oligonucleotide probes or HLA-C oligonucleotide probes.

The microarray will also typically comprise the probes at a surface density of about 250 to about 450 angstrom²/molecule, preferably about 325 to about 375 angstrom²/molecule.

In another aspect, the present invention provides a method of preparing an array of covalently-attached oligonucleotide probes, the method comprising;

(a) contacting a solid support with an aminoalkyltrialkoxysilane in the vapor phase at reduced pressure to form an aminoalkylsilane-derivatized solid support;

(b) contacting the aminoalkylsilane-derivatized solid support with a linking group to covalently attach the linking group to the aminoalkylsilane-derivatized solid support to form a linking group-modified solid support; and

(c) attaching a plurality of oligonucleotide probes to the linking group-modified solid support to form the array of covalently-attached oligonucleotide probes.

In still another aspect, the present invention provides a method of HLA Class I tissue typing, the method comprising:

(a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;

5 (b) contacting, under hybridization conditions, the labeled, single-stranded
DNA sample with a microarray prepared by the methods described herein; and
10 (c) detecting a hybridization pattern for the DNA sample and assigning an
HLA Class I allele type by analysis of the hybridization pattern.

5 In yet another aspect, the present invention provides a method of HLA tissue
typing, said method comprising:

15 (a) selectively amplifying the HLA regions in a genomic sample using
asymmetric PCR and labeled primers to form a labeled, single-stranded DNA sample;
20 (b) contacting under hybridization conditions the labeled, single-stranded
DNA sample with an HLA microarray prepared by the methods described herein; and
(c) detecting a hybridization pattern for the DNA sample and assigning an
HLA allele type by analysis of the hybridization pattern.

25 15 A method of HLA-B tissue typing, said method comprising:
(a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled
primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;
30 (b) contacting under hybridization conditions, the labeled, single-stranded
DNA sample with an HLA-B microarray described herein; and
20 (c) detecting a hybridization pattern for the DNA sample and assigning an
HLA-B allele type by analysis of the hybridization pattern.

DETAILED DESCRIPTION

25 The present invention provides compositions and methods for detecting
polymorphisms in genes. In particular, the invention provides compositions and methods for
40 determining the genotype of an individual at a particular allele. Within a particularly
preferred embodiment, the alleles are alleles in the major histocompatibility locus. Within
one embodiment, the alleles are alleles of a HLA Class I gene. Within another embodiment,
45 30 the alleles are alleles of a HLA Class II gene. Within yet another embodiment, the HLA
Class I alleles are alleles of HLA-A, HLA-B or HLA-C.

5

Overview of oligonucleotide array technology

10

Oligonucleotide array technology has become a valuable tool in modern molecular biology. The combination of a standard nucleic acid hybridization approach with innovative high-density DNA array technology has proven to be a powerful method for high-throughput DNA sequence analysis. The technology has been successfully applied to many fields of molecular biology, including large scale gene discovery, monitoring the expression of thousands of genes, mutation and polymorphism detection, as well as mapping of genomic clones.

15

20

Solid support-based oligonucleotide arrays can be manufactured either by *in situ* combinatorial oligonucleotide synthesis or by conventional oligonucleotide synthesis followed by immobilization of the oligonucleotide onto the solid support.

25

30

When the arrays are used for sequencing, a sample of DNA is amplified (typically using the polymerase chain reaction (PCR)), labeled with a detectable tag and hybridized to the oligonucleotide array in which the locations of various probe oligonucleotides are known. The hybridization pattern is then measured by, for example, fluorescence scanning, and the intensity of each hybridization signal is quantified using a "spot-finding" software. The pattern provides the practitioner with a sequence for an unknown piece of DNA.

20 Synthesis of oligonucleotide arrays on solid supports

35

40

The attachment of nucleic acids or oligonucleotide molecules to solid supports to create highly dense patterns of diverse oligonucleotide probes on a single surface has been demonstrated by, for example, Maskos and Southern (*Nuc. Acids. Res.* 20:1679-1684 (1992)), Blanchard and Hood (*Bioelectronics* 11:687-690 (1996)), and Fodor et al. (*Science* 251:767-773 (1991)). Arrays with as many as 10^5 different types of oligonucleotide probes on a single silicon or glass surface have been constructed. The fidelity of these arrays has been demonstrated by hybridization of DNA labeled with a fluorescent or radioisotope tag.

45

50

Two methodologies have been used to synthesize oligonucleotide arrays. Saiki et al. (*Proc. Natl. Acad. Sci. USA.* 86:6230-6234 (1989)) and Chrisey et al. (*Nuc. Acids Res.* 24:3040-3047 (1996)), for example, demonstrated that presynthesized oligonucleotide probes can be delivered to a solid support by high-speed robotics, and then immobilized on the surface. The resolution of the resulting oligonucleotide array is determined by both the

55

5 spatial resolution of the delivery systems and the physical space requirement of the delivered
oligonucleotide solution volume. The surface density of the immobilized oligonucleotides
varies greatly with different solid surface and linkage chemistries (Guo, et al., *Nuc. Acids*
10 *Res.* 22:5456-5465 (1994); Fahy, et al., *Nuc. Acids Res.* 21:1819-1826 (1993); Wolf, et al.,
5 *Nuc. Acids Res.* 15:2911-2926 (1987); and Ghosh, et al., *Nuc. Acids Res.* 15:5353-5372
(1987)).

15 In another approach oligonucleotide probes are synthesized directly onto the
solid support, nucleotide by nucleotide, through a series of coupling and deprotection steps.
Both conventional solid-phase oligonucleotide synthesis methods and light-directed
20 combinatorial synthesis methods have been successfully applied in this *in situ* fabrication
process (Fodor et al., *supra* (1991) and Gilham, *Biochemistry* 7:2809-2813 (1968)). High
30 reaction yields in both the coupling and the deprotection steps are critical for the success of
in situ synthesis. The preparation of *in situ* arrays can be automated and thereby increase the
complexity of the array compared to the use of presynthesized oligonucleotides.

25 15 a) **Spatially-resolved attachment chemistry**

Preferably, an oligonucleotide is immobilized onto a solid support through a
30 single covalent bond. Gilham (*Biochemistry*, 7:2809-2813 (1968)), for example, described
the attachment of DNA molecules to paper using carbodiimide via the 5'-end terminal
20 phosphate group. Suitable supports for covalent immobilization of DNA include glass,
acrylamide gel, latex particles, controlled pore glass, dextran supports, polystyrene matrices
35 and avidin-coated polystyrene beads and have been described (Guo, et al., *Nuc. Acids Res.*
22:5456-5465 (1994); Fahy, et al., *Nuc. Acids Res.* 21:1819-1826 (1993); Wolf, et al., *Nuc.*
Acids Res. 15:2911-2926 (1987); Ghosh, et al., *Nuc. Acids Res.* 15:5353-5372 (1987);
25 Gingeras et al., *Nuc Acids Res.* 15:5773-5790 (1987); Rasmussen et al., *Anal. Biochem.*
198:138-142 (1991); and Lund et al., *Nuc. Acids Res.* 16:10861-10880 (1988)). Several
40 other solid supports, such as nitrocellulose and nylon membranes were employed for
oligonucleotide immobilization using UV-activated DNA-surface cross-linking chemistry
(Meinkoth and Wahl, *Anal. Biochem.* 138:267-284 (1984)). However, in these cases, DNA
45 molecules were non-covalently bound to the surface at multiple sites, hampering
30 reproducibility and stability.

Fodor, et al. (*supra* (1991)) demonstrated the use of photolithographic
50 technology to synthesize high-density oligonucleotide arrays on silicon substrates. In this

5 process, crosslinkers are first made by exposing a photochemically-labile organosilane
surface to UV light. The resulting pattern is then reacted with heterobifunctional
crosslinking molecules. The oligonucleotide molecules are then bound to these crosslinkers
10 to form a well-defined DNA pattern on the surface. Spatial resolution of 1 micron per DNA
spot is feasible using this approach.

Although newer chemistries have greatly improved the density of arrays
15 compared to earlier methods, the capacity of these arrays has been limited chiefly by the
two-dimensional nature of the solid surface. Three-dimensional immobilization matrices
have been developed to increase capacity. Yershor, et al. (*Genetics* 93:4913-4918 (1996)),
20 for example, have produced DNA arrays by immobilizing oligonucleotides in acrylamide gel
at a density of 20,000 to 30,000 different oligonucleotide probes per cm², two orders of
magnitude higher than the capacity of two-dimensional supports. The three-dimensional
support permits high oligonucleotide loading and enhanced hybridization. However,
because only short oligonucleotides can diffuse into gel matrix, the application of this
25 approach is limited.

b) Spatially addressable parallel chemical synthesis

30 Solid phase DNA synthesis can be accomplished with a number of different
chemistries. Froehler et al. (*Nuc. Acids Res.* 14:5399-5407 (1986) and McBride and
20 Caruthers (*Tetrahedron Lett.* 24:245-248 (1983) have demonstrated solid phase DNA
synthesis chemistries utilizing H-phosphonate and phosphoramidites, which covalently
attach an organic linker molecule to a surface and build the oligonucleotide off the terminus
35 of the linker through successive coupling and deprotection steps.

Based on this scheme, two distinct approaches have been developed to
25 construct surface-bound oligonucleotide arrays. One approach (Fodor, et al., *supra* (1991))
combines solid-phase DNA synthesis with semiconductor-based photolithography. The
major advantage of this approach is the potential to synthesize very high-density arrays
comprised of 50 micron spots or less. However, the major drawback to this approach is the
40 need for a photolithographic mask for each unique array of oligonucleotides. For example,
an array of 25-mers would require 100 different masks. The expense of synthesizing these
30 arrays is proportional to the number of unique masks.

In a second approach, Southern et al. (*supra*, 1994) used microfabricated ink-
50 jet pumps, similar to those used in certain ink-jet printers to deliver synthesis reagents onto

the surface of a solid support. Within this method, the surface is scanned across a set of ink-jet pumps using a computer-controlled x-y translation stage. In each coupling step, DNA monomers are delivered to the defined area at rates of several hundred drops per second. These *in situ* approaches permit large numbers of arrays of unlimited combinatorial matrices to be made in fairly few steps.

Each of these *in situ* approaches permit large numbers of arrays of unlimited combinatorial matrices to be made in fairly few steps.

Hybridization and detection

Hybridization of DNA to a solid support has similar thermodynamic behavior compared to hybridization of DNA in solution. The stability of the double helix can be characterized by its melting temperature, which is strongly dependent upon oligonucleotide sequence and composition of the solvent (Wetmur, *Crit. Rev. Biochem. & Mol. Bio.* 26:227-259 (1991)). This strong-dependence of the duplex stability on oligonucleotide sequence, especially for short oligonucleotides, makes it difficult to design adequately stringent conditions for hybridization with oligonucleotide arrays, which usually vary widely in base composition. Thus, a large number of false positive or negative signals may occur when hybridization is performed on complex oligonucleotide arrays. Several approaches have been employed to eliminate the sequence-dependence of the stability of duplexes. Utilization of tetramethylammonium chloride (TMAC) in the hybridization solution is the most popular approach (Wood, et al., *Proc. Natl. Acad. Sci. USA* 82:1585-1588 (1985) and Riccelli and Benight, *Nuc. Acids Res.* 21:3785-3788 (1993)). TMAC was found to neutralize stability of duplexes imparted by sequences and allow the stringency of hybridization to be controlled as a function of probe length. Similar "isostabilization" function has also been described for other reagents (Rees, et al., *Biochemistry* 32:137-144 (1993)).

The thermodynamic stability of solid-phase hybridization is also affected by differences between the perfectly matched duplex versus the mismatched duplex, which constitutes the fundamental limitation to sequence-specific recognition in hybridization. The binding of a probe mismatched at a single base is compared with that of a perfectly matched probe; the difference in duplex stability is used to identify the target sequence. In many cases, the differences in stability of a perfect match and a single-base mismatch are so small that discrimination between a perfect match and a single base mismatch cannot be achieved

5 using common hybridization-washing procedures. Guo et al. described an approach to substantially increase the discrimination of single-base mismatches by using artificial mismatches (Guo et al., *Nature Biotech.* 15:331-335 (1997)). In this approach, an
10 "artificial" mismatch is intentionally inserted into the oligonucleotide probe sequence, and the discrimination compares the stability of two mismatches versus one mismatch. An
5 enhancement of the discrimination, as high as 200% of differential melting temperature, is generally achieved in hybridization with oligonucleotide arrays.

15 *In vitro* data indicate that DNA hybridization in free solution and on surfaces is often a reaction rate-limited process. In a study of nitrocellulose membrane arrays, the
20 hybridization kinetics were found to be proportional to the concentration of immobilized DNA. Recently, Chan et al. proposed a mathematical model of hybridization on solid supports (Chan et al., *Biophysical J.* 69:2243-2255 (1995)). This theory hypothesizes two
25 different mechanisms by which DNA targets can hybridize with immobilized oligonucleotide probes: direct hybridization from solution and hybridization by DNA targets
15 that adsorb nonspecifically on the surface and then diffuse to the probes. The hybridization rate depends strongly on both the DNA diffusion constant in solution and the DNA
adsorption/desorption constant on surface.

30 Nanogen Inc. has developed a practical system to accelerate the hybridization process using electric fields to facilitate the diffusion of DNA targets to the immobilized
20 probes (Sosnowski et al., *Proc. Natl. Acad. Sci. USA* 94:1119-1123 (1997) and Cheng et al., *Nature Biotech.* 16:541-546 (1998)). In this system, oligonucleotide arrays are synthesized
35 on the surface of a silicon electrode. DNA molecules, which have a large negative charge, can be moved in an electric field to an area of net positive charge and concentrate
significantly on the electrode surface. The concentrating effect accelerates the hybridization
25 of DNA targets. Another advantage of this system is the reversibility of the hybridization in
40 which non-specifically bound DNA target molecules can be easily removed from the oligonucleotide arrays by reversing the polarity of the field.

45 **Detection of hybridization events on solid supports**

30 Hybridization assays have been greatly simplified by the PCR. PCR can selectively amplify the number of copies of a particular DNA sequence of interest by 6 to 8
orders of magnitude (Saiki et al., *Science* 239:487-491 (1988)). This amplification process,
50 together with the high density of oligonucleotide arrays available with the solid-phase

5 synthesis, makes it much easier to generate detectable hybridization signals on a solid surface. As a result of this increased hybridization signal intensity, nonradioactive detection
10 methods are increasingly preferred for oligonucleotide arrays, especially in clinical applications of large numbers of DNA samples.

5 These advances notwithstanding, the two dimensional nature of oligonucleotide arrays and the need for extensive washing steps to remove mismatched and nonspecifically bound DNA target greatly limit the hybridization signal intensity. Several
15 detection methods are currently available of which the fluorescence-based methods are the most popular. Quantitative hybridization data available from these methods affords the
10 advantages of rapid image analysis, direct comparison and digital archiving. Both the intensity of the fluorescent signal and the background depend strongly on environmental factors, such as dryness of the surface and the support materials (Guo et al., *supra* (1994)). The influence of environmental factors to the strength of the signal and background mandates stringency for conditions and often precludes the use of highly fluorescent
25 supports, such as nylon membranes.

In the analysis of complex genome systems, the use of multiple fluorescent dyes to simultaneously distinguish different DNA molecules is an important methodologic advancement. DNA targets in hybridization systems can be fluorescently labeled either
30 directly or indirectly. The direct fluorescent label systems for DNA molecules include derivatives of fluorescein and rhodamine dyes, which can be easily attached to the end of DNA strand.

35 Biotin is the most commonly used indirect fluorescent label. Biotin can be easily incorporated into DNA molecules and detected using avidin or streptavidin by a covalently linked reporter group, such as alkaline phosphatase and horseradish peroxidase
25 (Rees and Kurz, *Nuc. Acids Res.* 12:3435-3439 (1984)). The indirect nature of the biotin labeling method limits the applicability for quantitative analysis, but the sensitivity of biotin assays are as high as that which can be achieved using radioisotopes.

40 The fluorescence detection systems require that excess label be washed off; furthermore, after hybridization real-time monitoring of the hybridization process is not
45 feasible. In order to observe ongoing hybridization events on the surface, surface-related detection methods have been developed. These methods are based on different optical phenomenon on the surface and can detect subtle changes such as the formation of DNA
50 duplexes on the surface, without interfering with the excess DNA in solution. Duplex

5 electron transfer, optical wave-guide, surface plasmon resonance and resonant mirror are a few examples of currently developed surface-based detection methods (Wood, *Microchem. J.* 47:330-337 (1993); Stimpson and Gordon, *Biomolecular Engineering* 13:73-80 (1996);
10 Wats et al., *Biosensor. Anal. Chem.* 67:4283-4289 (1995); and Stimpson et al., *Proc. Natl. Acad. Sci. USA* 92:6379-6380 (1995)). These methods have been tested for oligonucleotide array hybridization experiments utilizing a limited number of probes. The applicability of
15 these methods to complex oligonucleotide arrays has yet to be evaluated.

Embodiments of the Invention

I. Arrays of HLA Oligonucleotide Probes

20 The present invention provides an array of HLA oligonucleotide probes. The array is a useful tool for performing phenotypic analysis on a tissue sample to determine, for example, whether a particular donor is suitable for matching in tissue transplantation.

25 Generally, the array will comprise a series of oligonucleotide probes which represent at least 80%, preferably at least 90% and more preferably at least 98% of all known polymorphisms HLA Class I locus. In one preferred embodiment, the arrays will represent all known polymorphisms in exons 2 and 3 of the HLA Class I locus. The probes are provided on the
30 array at known or preselected positions to facilitate analysis. Additionally, the probes are generally covalently attached to the solid support using a linking group that is sufficient to provide optimum binding of a sample nucleic acid to the probe array.

35 As used herein, the term "nucleic acid" or "oligonucleotide" refers to a deoxyribonucleotide or ribonucleotide in either single- or double-stranded form. The term also encompasses nucleic-acid-like structures with synthetic backbones. DNA backbone
40 analogues provided by the invention include phosphodiester, phosphorothioate, phosphorodithioate, methylphosphonate, phosphoramidate, alkyl phosphotriester, sulfamate, 3'-thioacetal, methylene(methylimino), 3'-N-carbamate, morpholino carbamate, and peptide nucleic acids (PNAs); see *Oligonucleotides and Analogues, a Practical Approach*, edited by
45 F. Eckstein, IRL Press at Oxford University Press (1991); *Antisense Strategies*, Annals of the New York Academy of Sciences, Volume 600, Eds. Baserga and Denhardt (NYAS 1992); Milligan (1993) *J. Med. Chem.* 36:1923-1937; *Antisense Research and Applications* (1993, CRC Press). PNAs contain non-ionic backbones, such as N-(2-aminoethyl) glycine
50 units. Phosphorothioate linkages are described in WO 97/03211; WO 96/39154; Mata

(1997) Toxicol. Appl. Pharmacol. 144:189-197. Other synthetic backbones encompasses by the term include methyl-phosphonate linkages or alternating methylphosphonate and phosphodiester linkages (Strauss-Soukup (1997) Biochemistry 36:8692-8698), and benzylphosphonate linkages (Samstag (1996) Antisense Nucleic Acid Drug Dev 6:153-156).

The term nucleic acid is used interchangeably with gene, cDNA, mRNA, oligonucleotide primer, probe and amplification product.

The term "probe" or a "nucleic acid probe", as used herein, is defined to be a collection of one or more nucleic acid fragments whose hybridization to a sample can be detected. The probe may be unlabeled or labeled as described below so that its binding to the target or sample can be detected. The probe is produced from a source of nucleic acids from one or more particular (preselected) portions of the genome, e.g., one or more clones, an isolated whole chromosome or chromosome fragment, or a collection of polymerase chain reaction (PCR) amplification products. Alternatively, the probes of the present invention are synthesized and have sequences corresponding to a source of nucleic acids.

The probes of the present invention correspond to or are produced from nucleic acids found in the regions described herein. The probe or genomic nucleic acid sample may be processed in some manner, e.g., by removal of repetitive nucleic acids or enrichment with unique nucleic acids. The word "sample" may be used herein to refer not only to detected nucleic acids, but to the detectable nucleic acids in the form in which they are applied to the target. The probe may also be immobilized on a solid surface (e.g., nitrocellulose, glass, quartz, fused silica slides), as in an array. Techniques capable of producing high density arrays can also be used for this purpose (see, e.g., Fodor, *supra* (1991); Johnston, *Curr. Biol.* 8:R171-R174 (1998); Schummer, *Biotechniques* 23:1087-1092 (1997); Kern, *Biotechniques* 23:120-124 (1997); U.S. Patent No. 5,143,854). One of skill will recognize that the precise sequence of the particular probes described herein can be modified to a certain degree to produce probes that are "substantially identical" to the disclosed probes, but retain the ability to specifically bind to (i.e., hybridize specifically to) the same targets or samples as the probe from which they were derived (see discussion above). Such modifications are specifically covered by reference to the individual probes described herein.

The term a "nucleic acid array" as used herein is a plurality of nucleic acid molecules (probes) immobilized on a solid surface (e.g., nitrocellulose, glass, quartz, fused silica slides and the like) to which sample nucleic acids are hybridized. The nucleic acids may contain sequence from specific genes or clones, such as the probes of the invention, as

disclosed herein. Other probes optionally contain, for instance, reference sequences. The probes of the arrays may be arranged on the solid surface at different densities. The probe densities will depend upon a number of factors, such as the nature of the label, the solid support, and the like.

The array components are described in detail below.

Solid supports

The solid support used in the present invention may be biological, nonbiological, organic, inorganic, or a combination of any of these, existing as particles, strands, precipitates, gels, sheets, tubing, spheres, containers, capillaries, pads, slices, films, plates, slides, etc. The solid support is preferably flat but may take on alternative surface configurations. For example, the solid support may contain raised or depressed regions on which synthesis takes place. In some embodiments, the solid support will be chosen to provide appropriate light-absorbing characteristics. For example, the support may be a polymerized Langmuir Blodgett film, functionalized glass, Si, Ge, GaAs, GaP, SiO₂, SiN₄, modified silicon, or any one of a variety of gels or polymers such as (poly)tetrafluoroethylene, (poly)vinylidene difluoride, polystyrene, polycarbonate, or combinations thereof. Other suitable solid support materials will be readily apparent to those of skill in the art. Preferably, the surface of the solid support will contain reactive groups, which could be carboxyl, amino, hydroxyl, thiol, or the like. More preferably, the surface will be optically transparent and will have surface Si—OH functionalities, such as are found on silica surfaces.

Linking groups

Attached to the solid support is an optional spacer or linking group. The spacer molecules are preferably of sufficient length to permit the oligonucleotide probes in the completed array to interact freely with molecules exposed to the array. The spacer molecules, when present, are typically 6-50 atoms long to provide sufficient exposure for the attached probes. The spacer will typically be comprised of a surface attaching portion and a longer chain portion. The surface attaching portion is that part of the linking group or spacer which is directly attached to the solid support. This portion can be attached to the solid support via carbon-carbon bonds using, for example, supports having (poly)trifluorochloroethylene surfaces, or preferably, by siloxane bonds (using, for example,

5 glass or silicon oxide as the solid support). Siloxane bonds with the surface of the support
are formed in one embodiment via reactions of surface attaching portions bearing
trichlorosilyl or trialkoxysilyl groups. The surface attaching groups will also have a site for
10 attachment of the longer chain portion. For example, groups which are suitable for
5 attachment to a longer chain portion would include amines, hydroxyl, thiol, and carboxyl.
Preferred surface attaching portions include aminoalkylsilanes and hydroxyalkylsilanes. In
particularly preferred embodiments, the surface attaching portion of the linking group is
15 either aminopropyltriethoxysilane or aminopropyltrimethoxysilane.

The longer chain portion can be any of a variety of molecules which are inert
10 to the subsequent conditions necessary for attaching the oligonucleotide probes, or for
hybridization of a sample to the probe array. These longer chain portions will typically be
ethylene glycol oligomers containing 2-14 monomer units, diamines, diacids, amino acids,
peptides, or combinations thereof. In some embodiments, the longer chain portion is a
20 polynucleotide (e.g., a 15-mer of poly dT). Additionally, for use in synthesis of the probe
arrays, the linking group will typically have a protecting group, attached to a functional
25 group (i.e., hydroxyl, amino or carboxylic acid) on the distal or terminal end of the chain
portion (opposite the solid support). After deprotection and coupling, the distal end is
covalently bound to an oligonucleotide probe (e.g., an HLA Class I oligonucleotide probe).

20 HLA Oligonucleotide Probes

The key feature of the oligonucleotide array assay is the high redundancy of
35 oligonucleotide probes. In one embodiment of the invention, oligonucleotide probes were
designed to represent at least 80%, preferably at least 90% and more preferably at least 98%
of the known polymorphisms in exon 2 and exon 3 of HLA-B. Known polymorphisms are
25 those that have appeared in the literature or are available from a searchable database of
sequences. A panel of 68 20-mer oligonucleotide probes were designed for polymorphisms
in exon 2 and 70 20-mers were designed for exon 3. All known single allele in either
homozygous samples or heterozygous samples could be distinguished from its hybridization
45 pattern with this set of oligonucleotide probes, with the exception of three allele pairs.

30 The majority of individuals are heterozygous for two different HLA-B alleles.
Sequence polymorphisms or "motifs" can be shared among families of HLA-B alleles at a
given locus. Therefore, when both HLA-B alleles are co-amplified in PCR, more than one
50 combination of two alleles may produce identical patterns of hybridization to

5 oligonucleotide probes. Although alleles can be amplified separately with additional
allele-specific PCR reactions, a multiplicity of amplification steps diminishes overall
efficiency. The challenge of any molecular method is to identify all known coding region
10 polymorphisms that would enable each allele to be unambiguously assigned. As used
5 herein, the term "allele" refers to a specific version of a nucleotide sequence at a
polymorphic genetic locus. A computer simulation using this oligonucleotide array has
shown that all known single alleles in either homozygous samples or heterozygous samples
15 could be distinguished from its hybridization pattern with this set of oligonucleotide probes,
with the exception of five allele pairs mentioned above.

10 The fidelity of the hybridization assay is governed by the stability differences
between perfectly matched and mismatched duplexes. Within one embodiment a single set
of hybridization conditions that could provide a clear discrimination between matches and
mismatches for all polymorphisms in each exon was determined. In order for the melting
20 temperature of the probe sequences to be comparable, probes were designed with careful
attention to probe size, base composition, and placement of mismatched position within the
25 hybridization sequence.

Oligonucleotide probes of different lengths (15, 18 and 20 nucleotides) were
30 tested to optimize the hybridization signal intensity and hybridization specificity. Probes
were immobilized on solid supports and hybridized with PCR products. No signal was
20 generated from 15-mer probes, and very weak signals were produced with 18-mer probes;
the strongest signals were obtained with 20-mer probes. Thus, probes of between 17 and 23
35 nucleotides are useful within this invention. Within one embodiment, oligonucleotide
probes of 20 nucleotides were used.

The length of the spacer between the support and the hybridization sequence
25 influences the efficiency of hybridization (Guo et al, *Nuc. Acids Res.* 22:5456-5465 (1994)).
When large DNA fragments, such as PCR products, are allowed to hybridize with short
oligonucleotide probes immobilized on solid supports, adequate distance between the
hybridization sequence and the solid surface is required in order to achieve the efficient
45 hybridization. This is due to the steric interference between large DNA molecules and the
support. Within one embodiment of the invention, a 15-mer dT spacer was employed in
30 each oligonucleotide probe to provide adequate space between hybridization sequence and
the support. Although requiring extra expense in oligonucleotide synthesis, the 15-mer
50 spacer was essential to optimize hybridization signals. Each completed probe contained a 5'

amino group for immobilization chemistry, a 20-nucleotide hybridization sequence, and a 15-mer dT spacer between them.

As noted above, the oligonucleotide probes useful in this aspect of the invention are those probes that represent at least 80%, preferably 90%, more preferably 98% and most preferably all the known polymorphisms in exons 2 and 3 of the HLA Class I locus. The probes will generally comprise from about 17 to 23 nucleic acid residues (excluding a linking oligonucleotide) with those having about 20 nucleic acid residues being preferred.

In a preferred embodiment, the HLA Class I oligonucleotide probes are HLA-A oligonucleotide probes, HLA-B oligonucleotide probes or HLA-C oligonucleotide probes. In one group of particularly preferred embodiments, the oligonucleotide probes are those HLA-B probes provided in Tables 1 and 2.

TABLE 1

Probe	Location	Sequence	Seq. I.D. No.
PCR Probe HLA Exon Location 5-24			
A1	05—24	5'TCACACCCTCCAGAGCATGT3'	1
A2	05—24	5'TCACATCATCCAGAGGATGT3'	2
A3	05—24	5'TCACACTTGGCAGACGATGT3'	3
A4	05—24	5'TCACACCCTCCAGTGGATGT3'	4
A5	05—24	5'TCACACTTGGCAGAGGATGT3'	5
A6	05—24	5'TCACACCCTCCAGACGATGT3'	6
A7	05—24	5'TCACACCCTCCAGAAATATGT3'	7
A8	05-24	5'TCACATCATCCAGAGCATGT3'	8
A9	05—24	5'TCACACCATCCAGAGGATGT3'	9
A10	05-24	5'TCACATCATCCAGGTGATGT3'	10
A11	05—24	5'TCACACCCTCCAGAGGATGT3'	11
PCR Probe HLA Exon Location 21-40			
B1	21—40	5'ATGTACGGCTGCGACGTGGG3'	12
B2	21—40	5'ATGTATGGCTGCGACCTGGG3'	13

5

10

15

B3	21—40	5'ATGTTTGGCTGCGACGTGGG3'	14
B4	21—40	5'ATGTAAGGCTGCGACGTGGG3'	15
B5	21—40	5'ATGTCTGGCTGCGACGTGGG3'	16
B6	21—40	5'ATGTACGGCTGCGACCTGGG3'	17
5 B7	21—40	5'ATGTTTGGCTGCGACCTGGG3'	18
B8	21—40	5'ATGTATGGCTGCGACATGGG3'	19
B9	21—40	5'ATGTATGGCTGCGACGTGGG3'	20

PCR Probe HLA Exon Location 41-60

20

10 C1	41—60	5'GCCCCACGGGCGCCTCCTCC3'	21
C2	41—60	5'GCCCCACGGGCGCTTCCTCC3'	22
C3	41—60	5'GCCCCACGGGCGCCTCCTCC3'	23

PCR Probe HLA Exon Location 61-80

25

30

35

40

15 D1	61—80	5'GCGGGCATGACCAGTACGCC3'	24
D2	61—80	5'GCGGGCATAACCAGTACGCC3'	25
D3	61—80	5'GCGGGCATAACCAGTTAGCC3'	26
D4	61—80	5'GCGGGTATAACCAGTTCGCC3'	27
D5	61—80	5'GCGGGCATGACCAGTCCGCC3'	28
20 D6	61—80	5'GCGGGTATGACCAGTCCGCC3'	29
D7	61—80	5'GCGGGTACCACCAGGACGCC3'	30
D8	61—80	5'GCGGGCATGACCAGTTCGCC3'	31
D9	61—80	5'GCGGGCATAACCAGTTCGCC3'	32
D10	61—80	5'GCGGGTATGACCAGGACGCC3'	33
25 D11	61—80	5'GCGGGTATAACCAGTTAGCC3'	34
D12	61—80	5'GCGGGTATGACCAGTACGCC3'	35

PCR Probe HLA Exon Location 81-100

45

30

E1	81-100	5'TACGACGGCAAAGATTACAT3'	36
E2	81-100	5'TACGACGGCAAAGATTACAT3'	37

PCR Probe HLA Exon Location 111-130

50

F1	111-130	5'GAGGACCTGAGCTCCTGGAC3'	38
F2	111-130	5'GAGGACCTGCGCTCCTGGAC3'	39

55

5

PCR Probe HLA Exon Location 131-150

10	G1	131-150	5'CGCCGCGGACACGGCGGCTC3'	40
	G2	131-150	5'CGCGGCGGACACCGCGGCTC3'	41
5	G3	131-150	5'CGCCGCGGACAAGGCGGCTC3'	42
	G4	131-150	5'CGCCGCGGACACGGCAGCTC3'	43
15	G5	131-150	5'CGCCGCGGACACCGCGGCTC3'	44
	G6	131-150	5'CGCGGCGGACACGGCGGCTC3'	45

10 PCR Probe HLA Exon Location 151-170

20	H1	151-170	5'AGATCACCCAGCTCAAGTGG3'	46
	H2	151-170	5'AGATCTCCCAGCGCAAGTTG3'	47
	H3	151-170	5'AGATCACCCAGCGCAAGTGG3'	48

25

15 PCR Probe HLA Exon Location 171-190

	I1	171-190	5'GAGGCGGCCCGTGAGGCGGA3'	49
	I2	171-190	5'GAGGCGGCCCGTGTGGCGGA3'	50

30

PCR Probe HLA Exon Location 191-210

20	J1	191-210	5'GCAGCGGAGAGCCTACCTGG3'	51
	J2	191-210	5'GCAGGACAGAGCCTACCTGG3'	52
35	J3	191-210	5'GCAGTGGAGAGCCTACCTGG3'	53
	J4	191-210	5'GCAGCTGAGAACCTACCTGG3'	54
	J5	191-210	5'GCAGCGGAGAACCTACCTGG3'	55
40	25 J6	191-210	5'GCAGCTGAGAGCCTACCTGG3'	56

PCR Probe HLA Exon Location 211-230

	K1	211-230	5'AGGGCGAGTGCGTGGAGTGG3'	57
45	K2	211-230	5'AGGGCCTGTGCGTGGAGTGG3'	58
30	K3	211-230	5'AGGGCCTGTGCGTGGACGGG3'	59
	K4	211-230	5'AGGGCCTGTGCGTGGAGTCG3'	60
	K5	211-230	5'AGGGCACGTGCGTGGAGTCG3'	61
50	K6	211-230	5'AGGGCCTGTGCGTGGAGGGG3'	62

55

5

K7	211-230	5'AGGACCTGTGCGTGGAGTCG3'	63
K8	211-230	5'AGGGCACGTGCGTGGAGTGG3'	64

10

PCR Probe HLA Exon Location 231-250

5	L1	231-250	5'CTCCGCAGACACCTGGAGAA3'	65
	L2	231-250	5'CTCCGCAGATACCTGGAGAA3'	66

15

PCR Probe HLA Exon Location 257-276

	M1	257-276	5'GGACAAGCTGGAGCGCGCTG3'	67
10	M2	257-276	5'GGACACGCTGGAGCGCGCGG3'	68
20	M3	257-276	5'GGAGACGCTGCAGCGCGCGG3'	69

25

15

TABLE 2

Probe	Location	Sequence	Seq. I.D. No.
-------	----------	----------	---------------

PCR Probe HLA Exon Location 001-020

30

A1	01--20	5'GCTCCCACTTCATGAGGTAT3'	70
A2	01--20	5'GCTCCCACTCCATGAGGTAT3'	71

20

PCR Probe HLA Exon Location 021-040

35

B1	21--40	5'TTCTACACCTCCGTGTCCCG3'	72	
B2	21--40	5'TTCTACACCGCCATGTCCCG3'	73	
B3	21--40	5'TTCGACACCGCCATGTCCCG3'	74	
25	B4	21--40	5'TTCCACACCTCCGTGTCCCG3'	75
40	B5	21--40	5'TTCCACACCGCCATGTCCCG3'	76
	B6	21--40	5'TTCTACACCGCTATGTCCCG3'	77
	B7	21--40	5'TTCTACACCGCCGTGTCCCG3'	78

45

30 PCR Probe HLA Exon Location 041-060

50

C1	41--60	5'GCCCCGTCCGCGGGGAGCCCC3'	79
C2	41--60	5'GCCTGGCCGCGGGGAGCCCC3'	80
C3	41--60	5'GCCCCGCGCGGGGAGCCCC3'	81

55

5

PCR Probe HLA Exon Location 061-080

10

	D1	61-80	5'GCTTCATCTCAGTGGGCTAC3'	82
	D2	61-80	5'GCTTCATCACCGTGGGCTAC3'	83
5	D3	61-80	5'GCTTCATTGCAGTGGGCTAC3'	84
	D4	61-80	5'GCTTCATCGCAGTGGGCTAC3'	85

15

PCR Probe HLA Exon Location 081-100

20

	E1	81-100	5'GTGGACGACACCCAGTTCGT3'	86
10	E2	81-100	5'GTGGACGGCACCCAGTTCGT3'	87
	E3	81-100	5'GTGGACGACACGCTGTTCGT3'	88
	E4	81-100	5'GTGGACGACACGCAGTTCGT3'	89

25

PCR Probe HLA Exon Location 111-130

15	F1	111-130	5'AGCGACGCCACGAGTCCGAG3'	90
	F2	111-130	5'AGCGACGCCGCGAGTCCGAG3'	91

30

PCR Probe HLA Exon Location 096-115

	G1	96-115	5'TTCGTGCGGTTTCGACAGCGA3'	92
20	G2	96-115	5'TTCGTGAGGTTCGACAGCGA3'	93

35

PCR Probe HLA Exon Location 121-140

40

	H1	121-140	5'CGAGTCCGAGAGAGGAGCCG3'	94
	H2	121-140	5'CGAGTCCGAGGATGGCGCCC3'	95
25	H3	121-140	5'CGAGTCCGAGGACGGAGCCC3'	96
	H4	121-140	5'CGAGTCCGAGGAAGGAGCCG3'	97

45

PCR Probe HLA Exon Location 141-160

30	I1	141-160	5'CGGGCGCCATGGATAGAGCA3'	98
	I2	141-160	5'CGGGCGCCGTGGGTGGAGCA3'	99
	I3	141-160	5'CGGGCGCCGTGGATAGAGCA3'	100

50

55

5

PCR Probe HLA Exon Location 161-180

10

J1	161-180	5'GGAGGGGCCGGAATATTGGG3'	101
J2	161-180	5'AGAGGGGCCGAGTATTGGG3'	102
J3	161-180	5'GGAGGGGCCGAGCATTGGG3'	103
J4	161-180	5'GGAGGGGCCGAGTATTGGG3'	104

15

PCR Probe HLA Exon Location 181-200

20

25

30

K1	181-200	5'ACCGGAACACACAGATCTAC3'	105
K2	181-200	5'ACCGGAACACACAGATCTTC3'	106
K3	181-200	5'ACCGGGAGACACAGATCTCC3'	107
K4	181-200	5'ACCGGAACACACAGATCTGC3'	108
K5	181-200	5'ACCGGAACACACAGATCTCC3'	109
K6	181-200	5'ACCGGGAGACACGGAACATG3'	110
K7	181-200	5'ACCGGGATACACAGATCTCC3'	111
K8	181-200	5'ACCGGGAGACACAGATCTGC3'	112
K9	181-200	5'ACCGGGAGACACAGAAGTAC3'	113
K10	181-200	5'ACCGGGAGACACGGAACATG3'	114
K11	181-200	5'ACCGGGAGACACAGATCTTC3'	115

20 PCR Probe HLA Exon Location 201-220

35

40

L1	201-220	5'AAGGCCCAGGCACAGACTGA3'	116
L2	201-220	5'AAGACCAACACACAGACTTA3'	117
L3	201-220	5'AAGGCCTCCGCGCAGACTTA3'	118
L4	201-220	5'AAGGCCAAGGCACAGACTTA3'	119
L5	201-220	5'AAGGCCAAGGCACAGACTGA3'	120
L6	201-220	5'AAGCGCCAGGCACAGACTGA3'	121
L7	201-220	5'AAGACCAACACACAGACTGA3'	122

45

PCR Probe HLA Exon Location 216-235

50

M1	216-235	5'ACTGACCGAGAGAGCCTGCG3'	123
M2	216-235	5'ACTTACCGAGAGAACCTGCG3'	124
M3	216-235	5'ACTTACCGAGAGAGCCTGCG3'	125
M4	216-235	5'ACTGACCGAGAGGACCTGCG3'	126

55

5

M5	216-235	5'ACTTACCGAGAGGACCTGCG3'	127
M6	216-235	5'ACTGACCGAGTGAGCCTGCG3'	128
M7	216-235	5'ACTGACCGAGTGGGCCTGCG3'	129
M8	216-235	5'ACTGACCGAGAGAACCTGCG3'	130

10

5

PCR Probe HLA Exon Location 231-250

15

N1	231-250	5'CTGCGCACCGCGCTCCGCTA3'	131
N2	231-250	5'CTGCGGATCGCGCTCCGCTA3'	132
N3	231-250	5'CTGCGGACCCTGCTCCGCTA3'	133
N4	231-250	5'CTGCGGAACCTGCTCCGCTA3'	134
N5	231-250	5'CTGCGGAACCTGCGCGGCTA3'	135

20

PCR Probe HLA Exon Location 251-270

25

O1	251-270	5'CTACAACCAGAGCGAGGACG3'	136
O2	251-270	5'CTACAACCAGAGCGAGGCCG3'	137

15

30

The oligonucleotide probes used in the present invention can be prepared by any of a variety of methods. Briefly, the probes can be prepared using i) solution or solid phase methods, followed by attachment to the solid support, or ii) solid phase methods wherein the probes are constructed on the array surface.

20

35

Solution or solid phase methods

40

Detailed descriptions of the procedures for solution and solid phase synthesis of nucleic acids by phosphite-triester, phosphotriester, and H-phosphonate chemistries are widely available. For example, the solid phase phosphoramidite triester method of Beaucage and Carruthers using an automated synthesizer is described in, e.g., Itakura, U.S. Pat. No. 4,401,796; Carruthers, U.S. Pat. Nos. 4,458,066 and 4,500,707. See also Necdham-VanDevanter, *Nucleic Acids Res.* 12:6159-6168 (1984); Beigelman *Nucleic Acids Res* 23:3989-3994 (1995); OLIGONUCLEOTIDE SYNTHESIS: A PRACTICAL APPROACH, Gait (ed.), IRL Press, Washington D.C. (1984), see Jones, chapt 2, Atkinson, chapt 3, and Sproat, chapt 4; Froehler, *Tetrahedron Lett.* 27:469-472 (1986); Froehler, *Nucleic Acids Res.* 14:5399-5407 (1986). Methods to purify oligonucleotides include native acrylamide gel electrophoresis, anion-exchange HPLC, as described in Pearson *J. Chrom.* 255:137-149

45

30

50

55

(1983). The sequence of the synthetic oligonucleotide can be verified using any chemical degradation method, e.g., see Maxam (1980) *Methods in Enzymology* 65:499-560, Xiao *Antisense Nucleic Acid Drug Dev* 6:247-258 (1996), or for solid-phase chemical degradation procedures, Rosenthal, *Nucleic Acids Symp. Ser.* 18:249-252 (1987).

Solid-support based oligonucleotide synthesis

An array of oligonucleotide probes at known locations on a single substrate surface can be formed using a variety of techniques known to those skilled in the art of polymer synthesis on solid supports. For example, "light directed" methods (which are one technique in a family of methods known as VLSIPS™ methods) are described in U.S. Patent No. 5,143,854, previously incorporated by reference. The light directed methods discussed in the '854 patent involve activating predefined regions of a substrate or solid support and then contacting the substrate with a preselected monomer solution. The predefined regions can be activated with a light source shown through a mask (much in the manner of photolithography techniques used in integrated circuit fabrication). Other regions of the substrate remain inactive because they are blocked by the mask from illumination and remain chemically protected. Thus, a light pattern defines which regions of the substrate react with a given monomer. By repeatedly activating different sets of predefined regions and contacting different monomer solutions with the substrate, a diverse array of polymers is produced on the substrate. Of course, other steps such as washing unreacted monomer solution from the substrate can be used as necessary.

Other useful techniques include mechanical techniques (e.g., flow channel, spotting or pin-based methods). In each of the "flow channel" or "spotting" methods, certain activated regions of the substrate are mechanically separated from other regions when the monomer solutions are delivered to the various reaction sites.

A typical "flow channel" method applied to the compounds and libraries of the present invention can generally be described as follows. Diverse probe sequences are synthesized at selected regions of a substrate or solid support by forming flow channels on a surface of the substrate through which appropriate reagents flow or in which appropriate reagents are placed. For example, assume a monomer "A" is to be bound to the substrate in a first group of selected regions. If necessary, all or part of the surface of the substrate in all or a part of the selected regions is activated for binding by, for example, flowing appropriate reagents through all or some of the channels, or by washing the entire substrate with

5 appropriate reagents. After placement of a channel block on the surface of the substrate, a reagent having the monomer A flows through or is placed in all or some of the channel(s). The channels provide fluid contact to the first selected regions, thereby binding the monomer
10 A on the substrate directly or indirectly (via a spacer) in the first selected regions.

5 Thereafter, a monomer B is coupled to second selected regions, some of which may be included among the first selected regions. The second selected regions will be in fluid contact with a second flow channel(s) through translation, rotation, or replacement of
15 the channel block on the surface of the substrate; through opening or closing a selected valve; or through deposition of a layer of chemical or photoresist. If necessary, a step is performed for activating at least the second regions. Thereafter, the monomer B is flowed
20 through or placed in the second flow channel(s), binding monomer B at the second selected locations. In this particular example, the resulting sequences bound to the substrate at this stage of processing will be, for example, A, B, and AB. The process is repeated to form an array of sequences of desired length at known locations on the substrate.

25 After the substrate is activated, monomer A can be flowed through some of the channels, monomer B can be flowed through other channels, a monomer C can be flowed through still other channels, *etc.* In this manner, many or all of the reaction regions are reacted with a monomer before the channel block must be moved or the substrate must be
30 washed and/or reactivated. By making use of many or all of the available reaction regions simultaneously, the number of washing and activation steps can be minimized.

35 One of skill in the art will recognize that there are alternative methods of forming channels or otherwise protecting a portion of the surface of the substrate. For example, according to some embodiments, a protective coating such as a hydrophilic or hydrophobic coating (depending upon the nature of the solvent) is utilized over portions of
40 the substrate to be protected, sometimes in combination with materials that facilitate wetting by the reactant solution in other regions. In this manner, the flowing solutions are further prevented from passing outside of their designated flow paths.

45 The "spotting" methods of preparing compounds and libraries of the present invention can be implemented in much the same manner as the flow channel methods. For example, a monomer A can be delivered to and coupled with a first group of reaction regions
50 which have been appropriately activated. Thereafter, a monomer B can be delivered to and reacted with a second group of activated reaction regions. Unlike the flow channel embodiments described above, reactants are delivered by directly depositing (rather than

5 flowing) relatively small quantities of them in selected regions. In some steps, of course, the entire substrate surface can be sprayed or otherwise coated with a solution. In preferred
10 embodiments, a dispenser moves from region to region, depositing only as much monomer as necessary at each stop. Typical dispensers include a micropipette to deliver the monomer solution to the substrate and a robotic system to control the position of the micropipette with
15 respect to the substrate. In other embodiments, the dispenser includes a series of tubes, a manifold, an array of pipettes, or the like so that various reagents can be delivered to the reaction regions simultaneously.

Another method which is useful for the preparation of an array of diverse
10 oligonucleotides on a single substrate involves "pin based synthesis." This method is described in detail in U.S. Patent No. 5,288,514, previously incorporated herein by
20 reference. The method utilizes a substrate having a plurality of pins or other extensions. The pins are each inserted simultaneously into individual reagent containers in a tray. In a common embodiment, an array of 96 pins/containers is utilized.

25 Each tray is filled with a particular reagent for coupling in a particular chemical reaction on an individual pin. Accordingly, the trays will often contain different reagents. Since the chemistry used is such that relatively similar reaction conditions may be
30 utilized to perform each of the reactions, multiple chemical coupling steps can be conducted simultaneously. In the first step of the process, a substrate on which the chemical coupling steps are conducted is provided. The substrate is optionally provided with a spacer (e.g., 15-
35 mer of poly-dT) having active sites on which the oligonucleotide probes are attached or constructed.

II. Methods of Preparing Oligonucleotide Probe Arrays

40 25 In another aspect, the present invention provides methods of preparing oligonucleotide probe arrays. In this group of embodiments, oligonucleotide probe arrays are prepared by:

45 (a) contacting a solid support with an aminoalkyltrialkoxysilane in the vapor phase at reduced pressure to form an aminoalkylsilane-derivatized solid support;

30 (b) contacting the aminoalkylsilane-derivatized solid support with a linking group to covalently attach the linking group to the aminoalkylsilane-derivatized solid support to form a linking group-modified solid support; and
50

5

(c) attaching a plurality of oligonucleotide probes to the linking group-modified solid support to form the array of covalently-attached oligonucleotide probes.

10

The solid supports used in this aspect of the invention can be any of those described above which are conveniently derivatized with a vapor phase deposition of an aminoalkyltrialkoxysilane. Surprisingly, the use of this vapor phase deposition technique provides a particularly uniform surface for probe assembly and presentation.

15

The aminoalkyltrialkoxysilanes useful in this aspect of the invention are any of those that can be utilized in the vapor phase at temperatures of from about ambient temperature to about 150°C at pressures of from about 760 mmHg to about 0.1 mmHg. Typically, the aminoalkyl portion of the silane will be aminopropyl, aminoethyl or aminomethyl. The trialkoxysilane portion can be one in which the alkoxy groups are all the same (e.g., trimethoxysilane, triethoxysilane) or one in which the alkoxy groups are not all alike (e.g., dimethoxyethoxysilane). Accordingly, the aminoalkyltrialkoxysilane will typically be selected from aminopropyltrimethoxysilane, aminopropyltriethoxysilane, aminopropyldiethoxymethoxysilane, aminoethyltrimethoxysilane, and the like. More preferably, the aminoalkyltrialkoxysilane is aminopropyltrimethoxysilane.

20

25

30

As indicated above, a more uniform coating of amino groups on the solid support can be achieved by applying an aminoalkyltrialkoxysilane in the vapor phase, typically at reduced pressure. This can be accomplished by placing the solid support into a vacuum chamber, evacuating the chamber, and introducing the silane. In some embodiments, the vacuum chamber can be heated to facilitate silane vaporization and even coating of the solid support. For example, when aminopropyltrimethoxysilane is used, the pressure will typically be from about 5 to 35 mmHg and the vacuum chamber will be heated to a temperature of from about 60 to about 110°C. After a period of time sufficient for formation of an aminoalkylsilane-derivatized solid support, the support is removed from the vacuum chamber and rinsed to remove any unbound spacer.

35

40

The resultant support can then be contacted with a suitable amount of a linking group to covalently attach the linking group to the aminoalkylsilane-derivatized solid support. In some embodiments, the aminoalkylsilane-derivatized solid support will first be treated with a reagent capable of facilitating linking group attachment to the derivatized support. A variety of reagents are useful in this aspect of the invention including

45

30

50

55

5 diisocyanates, diisothiocyanates, dicarboxylic acids (and their activated esters), and the like. Particular preferred are diisothiocyanates (*e.g.*, 1,4-phenylenediisothiocyanate).

10 Once the solid support has been suitably derivatized, a linking group is attached to provide a spacing between the oligonucleotide probe and the support which is
5 optimized for interactions between the probes and the sample. As provided above, a variety of linking groups can be used in this aspect of the invention. Preferred groups are those that provide a spacing similar to that provided by a 15-mer poly dT spacing group.
15 Additionally, the linking group will have a reactive portion that is selected to be compatible with the amino group of the aminoalkylsilane-derivatized support, or with the functional
20 group present on the reagent used to facilitate linking group attachment (*e.g.*, the isothiocyanate portion of 1,4-phenylenediisothiocyanate). Accordingly, at the proximal end (that forming an attachment closest to the support), the linking group will have a functional group that is reactive with an amino moiety (*e.g.*, a carboxylic acid, anhydride,
25 isothiocyanate, and the like) or a functional group that is reactive with an isocyanate,
15 isothiocyanate or carboxylic acid moiety (*e.g.*, an amino group, a hydroxyl group or the like).

30 In a particularly preferred embodiment, the support is derivatized first with aminopropyltrimethoxysilane, followed by attachment of 1,4-phenylenediisothiocyanate, followed by attachment of a 15-mer oligonucleotide, preferably a 15-mer of poly-dT).

20 Following construction of the linking group-modified solid support, a plurality of oligonucleotide probes is attached to form an array of covalently-attached
35 oligonucleotide probes. In this aspect of the invention, the oligonucleotide probes can be any collection of nucleic acid probes or polymer. Preferably, the probes are those that represent all known polymorphisms in exons 2 and 3 of the HLA Class I locus. The probes
25 are typically 17 to 23 nucleotides in length, with those probes having about 20 nucleotides being particularly preferred. The most preferred HLA Class I oligonucleotide probes are shown in Tables 1 and 2. The oligonucleotide probes can be prepared by any conventional
40 methods known to those of skill in the art. Alternatively, the probes can be constructed on the array using the techniques described above (*e.g.*, photolithography, flow channel, ink-jet
45 spotting, and the like). In preferred embodiments, the probes are constructed using conventional solution or solid phase chemistry, then attached to the array's solid support component.
30

50 Construction of the present arrays is preferably carried out in a manner that ensures that the probes are at a surface density of about 250 to about 450

angstrom²/molecule, preferably about 325 to about 375 angstrom²/molecule. Methods of measuring probe density are well-known to those of skill in the art.

III. Diagnostic Methods Using Oligonucleotide Arrays

In order to determine donor/recipient compatibility in tissue transplants, the practitioner should compare the HLA Class I allele type of both the donor and the recipient. Tools to facilitate such tissue typing are provided herein.

Accordingly, in still another aspect, the present invention provides a method of HLA Class I tissue typing, the method comprising:

(a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;
(b) contacting the labeled, single-stranded DNA sample under hybridization conditions with an array of HLA Class I oligonucleotide probes prepared by the methods described herein; and

(c) detecting a hybridization pattern for the DNA sample and assigning an HLA Class I allele type by analysis of the hybridization pattern.

In this method, a tissue sample is obtained from a patient (either a potential donor or recipient) and exons 2 and 3 are amplified using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample. The tissue sample can be obtained from a variety of tissues, depending on the purpose of the diagnostic evaluation. The cell or tissue sample from which the nucleic acid sample is prepared is typically taken from a patient in need of HLA Class I tissue typing for transplant evaluation. Methods of isolating cell and tissue samples are well known to those of skill in the art and include, but are not limited to, aspirations, tissue sections, needle biopsies, and the like. Frequently the sample will be a "clinical sample" which is a sample derived from a patient, including sections of tissues such as frozen sections or paraffin sections taken for histological purposes. The sample can also be derived from supernatants (of cells) or the cells themselves from cell cultures, cells from tissue culture and other media.

After obtaining a suitable tissue sample, the nucleic acids of exons 2 and 3 are amplified using standard techniques such as PCR (*e.g.*, asymmetric PCR) and labeled primers. The term "labeled primer" as used herein refers to a nucleic acid template for PCR which is attached to a detectable composition, *i.e.*, a label. The detection of the label can be by, *e.g.*, spectroscopic, photochemical, biochemical, immunochemical, physical or chemical

5 means. For example, useful labels include ^{32}P , ^{35}S , ^3H , ^{14}C , ^{125}I , ^{131}I ; fluorescent dyes (e.g., FITC, rhodamine, lanthanide phosphors, Texas red), electron-dense reagents (e.g. gold),
10 enzymes, e.g., as commonly used in an ELISA (e.g., horseradish peroxidase, beta-galactosidase, luciferase, alkaline phosphatase), colorimetric labels (e.g. colloidal gold),
15 magnetic labels (e.g. DynabeadsTM), biotin, dioxigenin, or haptens and proteins for which antisera or monoclonal antibodies are available. The label can be directly incorporated into the nucleic acid to be detected. Additionally, the label can be attached by spacer arms of various lengths to reduce potential steric hindrance or impact on other useful or desired properties. See, e.g., Mansfield, *Mol Cell Probes* 9:145-156 (1995).

20 The terms "hybridizing specifically to" and "specific hybridization" and "selectively hybridize to," as used herein refer to the binding, duplexing, or hybridizing of a nucleic acid molecule preferentially to a particular nucleotide sequence under stringent conditions. The term "stringent conditions" or "hybridization conditions" refers to
25 conditions under which a probe will hybridize preferentially to its target subsequence, and to a lesser extent to, or not at all to, other sequences. A "stringent hybridization" and "stringent hybridization wash conditions" in the context of nucleic acid hybridization (e.g., as in array, Southern or Northern hybridizations) are sequence dependent, and are different under
30 different environmental parameters. An extensive guide to the hybridization of nucleic acids is found in, e.g., Tijssen (1993) *Laboratory Techniques in Biochemistry and Molecular Biology--Hybridization with Nucleic Acid Probes* part I, chapt 2, "Overview of principles of hybridization and the strategy of nucleic acid probe assays," Elsevier, NY ("Tijssen").
35 Generally, highly stringent hybridization and wash conditions are selected to be about 5°C lower than the thermal melting point (T_m) for the specific sequence at a defined ionic strength and pH. The T_m is the temperature (under defined ionic strength and pH) at which
40 50% of the target sequence hybridizes to a perfectly matched probe. Very stringent conditions are selected to be equal to the T_m for a particular probe. An example of stringent hybridization conditions for hybridization of complementary nucleic acids which have more than 100 complementary residues on an array or on a filter in a Southern or northern blot is
45 42°C using standard hybridization solutions (see, e.g., Sambrook and detailed discussion, below), with the hybridization being carried out overnight. An example of highly stringent
30 wash conditions is 0.15 M NaCl at 72°C for about 15 minutes. An example of stringent wash conditions is a 0.2x SSC wash at 65°C for 15 minutes (see, e.g., Sambrook (1989) *Molecular Cloning: A Laboratory Manual* (2nd ed.) Vol. 1-3, Cold Spring Harbor

Laboratory, Cold Spring Harbor Press, NY ("Sambrook") for a description of SSC buffer). Often, a high stringency wash is preceded by a low stringency wash to remove background probe signal. An example medium stringency wash for a duplex of, e.g., more than 100 nucleotides, is 1x SSC at 45°C for 15 minutes. An example of a low stringency wash for a duplex of, e.g., more than 100 nucleotides, is 4x to 6x SSC at 40°C for 15 minutes. Within one embodiment of the invention, hybridization at 37°C for two hours in 5xSSPE, 0.5% SDS was followed by two fifteen minute washes at stringent conditions in 20xSSPE, 0.2% SDS at 30°C.

In an array format a large number of different hybridization reactions can be run essentially "in parallel." This provides rapid, essentially simultaneous, evaluation of a large number of loci. Methods of performing hybridization reactions in array based formats are also described in, e.g., Pastinen (1997) *Genome Res.* 7:606-614; (1997) Jackson (1996) *Nature Biotechnology* 14:1685; Chee (1995) *Science* 274:610; WO 96/17958.

To optimize a given assay format, one of skill can determine sensitivity of label (e.g., fluorescence) detection for different combinations of membrane type, fluorochrome, excitation and emission bands, spot size and the like. Low fluorescence background membranes can be used (see, e.g., Chu (1992) *Electrophoresis* 13:105-114). The sensitivity for detection of spots ("target elements") of various diameters on the candidate membranes can be readily determined by, e.g., spotting a dilution series of fluorescently end labeled DNA fragments. These spots are then imaged using conventional fluorescence microscopy. The sensitivity, linearity, and dynamic range achievable from the various combinations of fluorochrome and solid surfaces (e.g., membranes, glass, fused silica) can thus be determined. Serial dilutions of pairs of fluorochrome in known relative proportions can also be analyzed. This determines the accuracy with which fluorescence ratio measurements reflect actual fluorochrome ratios over the dynamic range permitted by the detectors and fluorescence of the substrate upon which the probe has been fixed.

Arrays on solid surface substrates with much lower fluorescence than membranes, such as glass, quartz, or small beads, can achieve much better sensitivity. Substrates such as glass or fused silica are advantageous in that they provide a very low fluorescence substrate, and a highly efficient hybridization environment. Covalent attachment of the target nucleic acids to glass or synthetic fused silica can be accomplished according to a number of known techniques (described above). Nucleic acids can be conveniently coupled to glass using commercially available reagents. For instance, materials

5 for preparation of silanized glass with a number of functional groups are commercially available or can be prepared using standard techniques (see, e.g., Gait (1984) Oligonucleotide Synthesis: A Practical Approach, IRL Press, Wash., D.C.). Quartz cover
10 slips, which have at least 10-fold lower autofluorescence than glass, can also be silanized.

5 Alternatively, probes can also be immobilized on commercially available coated beads or other surfaces. For instance, biotin end-labeled nucleic acids can be bound to commercially available avidin-coated beads. Streptavidin or anti-digoxigenin antibody
15 can also be attached to silanized glass slides by protein-mediated coupling using e.g., protein A following standard protocols (see, e.g., Smith (1992) Science 258:1122-1126). Biotin or digoxigenin end-labeled nucleic acids can be prepared according to standard techniques.
20 Hybridization to nucleic acids attached to beads is accomplished by suspending them in the hybridization mix, and then depositing them on the glass substrate for analysis after washing. Alternatively, paramagnetic particles, such as ferric oxide particles, with or without avidin coating, can be used.

25 15 In one particularly preferred embodiment, probe nucleic acid is spotted onto a surface (e.g., a glass or quartz surface). The nucleic acid is dissolved in a mixture of dimethylsulfoxide (DMSO) and nitrocellulose and spotted onto amino-silane coated glass slides. Small capillaries tubes can be used to "spot" the probe mixture.
30

20 In related aspects, the present invention provides a method of HLA tissue typing, the method comprising:

- 35 (a) selectively amplifying the HLA regions in a genomic sample using asymmetric PCR and labeled primers to form a labeled, single-stranded DNA sample;
(b) contacting under hybridization conditions the labeled, single-stranded
25 DNA sample with an HLA microarray prepared by any of the methods described herein; and
40 (c) detecting a hybridization pattern for the DNA sample and assigning an HLA allele type by analysis of the hybridization pattern.

45 In another related aspect, the present invention provides a method of HLA-B tissue typing, the method comprising:

- 30 (a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;
50

(b) contacting under hybridization conditions, the labeled, single-stranded DNA sample with any or the HLA-B microarrays described herein; and
(c) detecting a hybridization pattern for the DNA sample and assigning an HLA-B allele type by analysis of the hybridization pattern.

EXAMPLES

The following examples are offered to illustrate, but not to limit the scope of the claimed invention.

EXAMPLE 1

This example illustrates the constructions of HLA-B oligonucleotide probes used in constructing the probe arrays.

The key feature of the oligonucleotide array assay is the high redundancy of oligonucleotide probes. Oligonucleotide probes were designed to represent all known polymorphisms in exon 2 and exon 3 of HLA-B. A panel of 68 20-mer oligonucleotide probes were designed for polymorphisms in exon 2 (Table 1) and 70 20-mers were designed for exon 3 (Table 2). All known single allele in either homozygous samples or heterozygous samples could be distinguished from its hybridization pattern with this set of oligonucleotide probes, with the exception of three allele pairs. All oligonucleotides were synthesized by Life Technologies, Inc. (Frederick, MD). The oligonucleotide probes used in manufacture of oligonucleotide arrays containing a 5'-amino group for immobilization chemistry. Concentrations of all oligonucleotides were determined by UV spectrophotometry at 260nm. Oligonucleotide probes of different lengths (15, 18 and 20 nucleotides) were tested to optimize the hybridization signal intensity and hybridization specificity. Probes were immobilized on solid supports and hybridized with PCR products. No signal was generated from 15-mer probes, and very weak signals were produced with 18-mer probes; the strongest signals were obtained with 20-mer probes. Therefore, a hybridization sequence of 20 nucleotides in length was chosen for all HLA-B oligonucleotides.

EXAMPLE 2

This example illustrates the construction of HLA-B oligonucleotide arrays.

HLA-B oligonucleotide arrays were constructed on treated microscopic slides by attaching pre-synthesized oligonucleotide probes. The arrays for exon 2 and exon 3 were fabricated on separate slides. Oligonucleotide probes were diluted to 500 pmole/mL, transferred into 96-well microtiter plate, applied to glass slides by using a Molecular Dynamic (Sunnyvale, CA) spotter system and immobilized on glass supports by covalent binding. Pre-cleaned microscope slides (Becton, Dickinson and Co., Portsmouth, NH) were immersed in concentrated HCl for 2 hours, then washed ten times with distilled water, five minutes per wash, and air dried. The cleaned slides were placed in a vacuum chamber with 700 microliters 3-aminopropyltrimethoxysilane (Aldrich Chemical, Milwaukee, WI) and the vacuum chamber was kept at 160°C and 30ppm Hg pressure for 3 hours. The slides were taken from the vacuum chamber and washed 5 times with acetone, five minutes per wash, and then treated for 2 hours with a solution of 0.2% 1,4-phenylene diisothiocyanate (Aldrich) in 10% pyridine/dimethyl formamide, and washed with acetone for 5 times, 5 minutes per wash. The activated glass slides may be stored indefinitely at 4°C in a vacuum dessicator containing anhydrous calcium chloride without discernible loss of activity. Oligonucleotide probes, labeled with 5'-amino group, were dissolved at concentration of 500pm/ul in water. Twenty-five microliters of the resultant solutions were transferred into 96-well microtiter plates. The filled microtiter plates were then placed into a Molecular Dynamic Generation II array spotter, along with the activated glass slides. The spotter system was designed to automatically collect samples from a 96-well microtiter plate with a 6-pen robot arm. Each pen collected from between 250 to 500 nL of solution per pen and deposited 0.25-1 nL on each slide, creating spots that ranged from 100-150 micron in diameter. The robot was programmed so that adjacent spots were spaced to avoid contact with each other, with 400-500 microns separating the centers of each spot. The precision of this measurement is about 10 microns. The robot rested on an optical table where 24 glass slides could be placed. At maximal capacity, 3,000 different oligonucleotides could be arrayed on one glass slide. The transfer of oligonucleotide solution from microtiter plate to glass slides was conducted at 50% humidity, and each oligonucleotide solution were spotted at four different places near each other on the glass slides. The spotting step was repeated three times for each glass slide. Slides spotted with oligonucleotide probes were then incubated at 37°C in a covered petri dish containing a small amount of water for 2 hours, removed, washed once with 1% NH₄OH, three times with water, and air-dried at room temperature. The slides were now ready for hybridization experiments. It is not

recommended that the slides be employed multiple times, as rapidly increased background is observed.

The oligonucleotide probes were linked to the glass surface by covalent bonding (Guo et al., *Nuc. Acids Res.* 22:5456-5465 (1994)). The immobilization chemistry included three steps: a) reaction of the pre-cleaned glass slides with aminopropyltrimethoxysilane vapor in vacuum chamber to generate an amino-derivatized surface; b) coupling of the amino group on the glass surface with excess p-phenylenediisothiocyanate to convert the amino groups to amino-reactive phenylisothiocyanate groups; and c) coupling of 5'-amino modified oligonucleotide probes to these amino-reactive groups to yield the surface-bound oligonucleotide.

Efficient and stable oligonucleotide coupling was achieved using this immobilization chemistry. Oligonucleotide arrays could be washed with water and stored at room temperature for a considerable period without any observable loss of oligonucleotides. The surface density of each oligonucleotide probe could be easily adjusted by changing the concentration of the oligonucleotide solution during the application step period.

EXAMPLE 3

This example illustrates the preparation of DNA samples.

Human genomic DNA samples encoding various HLA-B genotypes were studied. The OD 260/280 measurements of the DNA samples were used to assess the quality of genomic DNA. Exon 2 and exon 3 of HLA-B were amplified into fragments of 270 bp and 276 bp, respectively, using HLA-B specific primers, under optimized conditions (Petersdorf and Hansen, *Tissue Antigen* 46: 73-85 (1995)). One primer out of each primer pair was tagged with a 6-Rhodamine dye moiety (ABI) at its 5'-end for fluorescence detection after hybridization. The PCR products were purified by reverse-phase high performance liquid chromatography. The specificity of the amplified product was verified by conventional sequencing methods.

Although it is simpler to prepare double-stranded PCR products than single-stranded, hybridization of the double-stranded DNA to the support-bound oligonucleotide array will necessarily suffer from competition of the complementary strand with the oligonucleotide probes. Hybridization efficiency is much greater with the single-stranded HLA-B PCR product compared to the double-stranded PCR products (Guo

5 et al., *Nuc. Acids Res.* 22: 5456-5465 (1994)). Accordingly, several methods were explored
to generate single-stranded PCR products, including strand separation using
biotin-streptavidin interaction, I exonuclease digest and asymmetric PCR. Separation of
10 double-stranded DNA was accomplished by labeling one PCR primer with a biotin molecule
at its 5'-end; streptavidin-coated magnetic beads were added after PCR amplification; the
5 biotinylated PCR product was attached to the beads by biotin-streptavidin interaction. The
two DNA strands were separated through NaOH precipitation of the biotinylated strand
15 using a magnet (Guo et al., *supra*. (1994)).

The exonuclease digest approach utilized I exonuclease, which digests
20 double-stranded DNA molecules from its 5'-end while leaving single-stranded DNA
molecules intact. HLA-B was amplified from genomic DNA using one fluorescently tagged
primer and one unlabeled primer, and the PCR products were then incubated with I
exonuclease. The unlabeled strand of the PCR product was digested by the exonuclease
25 while the fluorescently tagged strand remained intact because the exonuclease activity on
that strand was blocked by the fluorescence label at its 5'-end. After enzyme digest, the
fluorescently labeled single-stranded DNA molecules were allowed to hybridize to the
oligonucleotide arrays.

Another approach for generating single-stranded DNA molecules is
30 asymmetric PCR. A two-step PCR strategy was designed in this approach. In the first step,
HLA-B was amplified by PCR using two primers to generate double-stranded PCR products;
20 in the second step, the PCR product obtained from the first amplification was amplified by
PCR with only one primer, so that only one DNA strand would be amplified in this step.
The single-stranded product generated in this approach had very high hybridization
35 efficiency when applied to the oligonucleotide array.

25 All three methods could efficiently generate single-stranded DNA product.
The strand separation method had the highest efficiency, but the high cost of the streptavidin
beads made it unsuitable for large-scale testing. The exonuclease digest method and the
asymmetric PCR method were both economical and efficient, but a higher concentration of
40 single-stranded PCR product could be generated through two amplification steps in the
asymmetric PCR approach. Therefore, the asymmetric PCR method was employed
30 exclusively in our DNA sample preparation. Human genomic DNA was extracted from
blood sample using standard procedures. The quality of DNA sample was tested by OD
50 260/280 measurement.

5 Exon 2 of HLA-B gene was amplified by two-step asymmetric PCR. In the
first step, the PCR primers were Exon 2 5'-primer (5'-GCTCCCACTCCATGAGGTAT-3';
SEQ ID NO: 138) and Exon 2 3'-primer (5'-CGGCCTCGCTCTGGTTGTAG-3'; SEQ ID
10 NO:139). The one hundred microliter amplification reaction contained 50 mM KCl, 10 mM
5 Tris-HCl, 1.5 mg MgCl₂, 10 mg of gelatin, 20 ng of genomic DNA, 2 microMoles of each
primer, 200 microMoles each of dATP, dCTP, dTTP and dGTP, and 2.5 U of Taq DNA
polymerase. The amplification reaction was performed in a Perkin-Elmer Cetus 9600
15 thermal cycler using 35 cycles of the following profile: 94°C for 30 seconds, 60°C for 1
minute and 72°C for 1 minute. The PCR mixture was then purified using a QIAGEN PCR
20 purification kit (QIAGEN Inc., Chatsworth, CA) to remove the excess primers. In the
second step, the PCR primer employed was a 5' Rhodamine-labeled Exon 2 3'-primer (SEQ
ID NO 139). The PCR was performed in 30 cycles using the following profile: 94°C for 30
seconds, 60°C for 1 minute and 72°C for 2 minutes.

Amplification of exon 3 of HLA-B was accomplished using Exon 3 5'-primer
25 (5'-ACCCGGTTTCATTTTCAGTTG-3'; SEQ ID NO:140) and Exon 3 3'-primer
(5'-CCCACTGCCCTGGTACC-3'; SEQ ID NO:141). The amplification reaction was
performed in 35 cycles of the following profile: 94°C for 30 seconds, 65°C for 1 minute and
30 72°C for 1 minute. To generate single-strand exon 3 product, the second PCR was
performed, employing a 5' Rhodamine-labeled 3 3'-primer (SEQ ID NO:141), in 30 cycles of
20 the following profile: 94°C for 1 minute, 65°C for 1 minute and 72°C for 2 minute.

35 EXAMPLE 4

The example illustrates the hybridization and detection of DNA samples to
the HLA-B microarrays.

25
40 The fidelity of the hybridization assay is governed by the stability differences
between perfectly matched and mismatched duplexes. It was desirable to find a single set of
hybridization conditions that could provide a clear discrimination between matches and
45 mismatches for all polymorphisms in each exon. In order for the melting temperature of the
30 probe sequences to be comparable, probes were designed with careful attention to probe size,
base composition, and placement of mismatched position within the hybridization sequence.

Single-stranded HLA-B, generated by asymmetric PCR using a fluorescently
50 labeled primer, was diluted using hybridization buffer and allowed to hybridize to the

oligonucleotide arrays for 3 hours. The glass slide was then washed with washing buffer at stringent conditions to remove mismatched DNA strands. Hybridization experiments designed to compare tetramethylammonium chloride (TMAC), an "isostabilization" reagent, and with buffer containing no TMAC generated the same hybridization patterns. This demonstrated that the melting temperatures of the HLA-B oligonucleotide sequences were comparable, and that a single set of conditions could be used for all HLA-B polymorphisms. For hybridization with exon 2 oligonucleotide arrays, fifty microliter solution of the single-stranded Rodamine-labeled PCR product of exon 2 in 5xSSPE, 0.5% SDS was applied to the array slide and covered with a cover glass, and incubated at 37°C for 2 hours. The glass slide was then washed with 20ml washing buffer (20xSSPE, 0.2% SDS) at 30°C twice, 15 minutes each. For hybridization with exon 3 oligonucleotide arrays, fifty microliter solution of the single-stranded Rodamine-labeled PCR product of exon 3 was added to the glass slides, and incubated at 30°C for 2 hours and then washed at room temperature twice.

After hybridization and washing process, fifty microliters of washing solution (2xSSPE, 0.2% SDS) was applied to the glass slide, and the slide was covered with a cover glass. This provides an aqueous environment for the fluorescence scanning. Positive hybridization results were detected by fluorescence scanning of the slide using a Molecular Dynamic array scanner. This instrument generated fluorescence images by scanning a laser beam over the sample surface in a raster pattern. The resulting fluorescence was monitored pixel-by-pixel through a bandpass filter. The spatial resolution of the scan was 10 microns per pixel. The fluorescence intensity of each pixel, measured by a PMT, was digitized to 16-bit precision, and the data saved to computer disk as a TIFF format file. After scanning, the fluorescence image was reconstructed from the digitized pixel intensities using image analysis software provided with the scanner. A "spot finding" program was used to verify the hybridization signals and to quantify signal intensities. A linear relationship between signal intensity and concentration of bound oligonucleotide was observed within a range of 0.5 fmole to 0.5 pmole. To calculate signal intensity, the ImageQuant software was used to sum pixel intensities within each spot image. The average value and standard deviation of pixel intensities would also be calculated and local background level subtracted. The signal-to-noise ratio was calculated as the fluorescence intensity level over background divided by the standard deviation of intensities.

5

EXAMPLE 5

The example illustrates HLA-B allele assignment.

10

5 HLA-B alleles were assigned by quantitative analysis of the hybridization pattern of the DNA sample. The oligonucleotide probes were assigned into different groups. The probes in each group would hybridize with the same 20-nucleotide region in either exon 2 or exon 3, and be complementary with sequence of different alleles. When hybridized with heterozygous DNA samples, 2 oligonucleotide probes in each group might be perfectly matched with the PCR product, each matched with a different allele. When hybridized with homozygous samples, one probe in each group would be perfectly matched with the PCR product. A theoretical hybridization pattern was generated for each allele by counting the probes matched with its sequence.

15

20

All hybridization signal intensities were quantified and ranked from the highest to the lowest in each probe group. When hybridized with homozygous samples, only one probe in each group produces positive signal as the perfect match. In samples heterozygous for two different HLA-B alleles, two probes with highest signal intensities in each group are selected as positive unless only one positive signal was shown in that group. Assignment of the alleles was accomplished by comparing the detected hybridization pattern, with the theoretical patterns of all known HLA-B alleles.

25

30

A blinded equivalency study of 60 different DNA samples that were previously typed using sequencing methods was conducted. HLA-B allele assignments were made by an independent observer who had no knowledge of the genotypes of the samples. The same alleles were assigned with the array method as were previously determined by sequencing for all 120 alleles in the study group.

35

40

It is understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and scope of the appended claims. All publications, patents, and patent applications cited herein are hereby incorporated by reference in their entirety for all purposes.

45

30

50

55

Claims

5

10

15

20

25

30

35

40

45

50

55

5

WHAT IS CLAIMED IS:

10

1. A microarray of oligonucleotides, said microarray comprising a plurality of HLA Class I oligonucleotide probes on a solid support, said plurality of probes being sufficient to represent at least 80% of known polymorphisms in the HLA Class I locus.

15

2. A microarray in accordance with claim 1, wherein said plurality of probes is sufficient to represent at least 90% of known polymorphisms in the HLA Class I locus.

20

3. A microarray in accordance with claim 1, wherein said plurality of probes is sufficient to represent at least 98% of known polymorphisms in the HLA Class I locus.

25

4. A microarray in accordance with claim 1, wherein each of said plurality of HLA Class I oligonucleotide probes is covalently attached to said solid support and has from 17 to 23 nucleotides.

30

5. A microarray in accordance with claim 4, wherein each of said plurality of HLA Class I oligonucleotide probes has 20 nucleic acids.

35

6. A microarray in accordance with claim 4, wherein said HLA Class I oligonucleotide probe is selected from the group consisting of HLA-A oligonucleotide probes, HLA-B oligonucleotide probes and HLA-C oligonucleotide probes.

40

7. A microarray in accordance with claim 6, wherein said HLA Class I oligonucleotide probe is selected from the group consisting of HLA-A exon 2 and exon 3 oligonucleotide probes, HLA-B exon 2 and exon 3 oligonucleotide probes and HLA-C exon 2 and exon 3 oligonucleotide probes.

45

8. A microarray in accordance with claim 6, wherein said HLA Class I oligonucleotide probe is selected from the group consisting of HLA-B exon 2 and exon 3 oligonucleotide probes.

50

9. A microarray in accordance with claim 4, wherein said solid support is a glass slide.

55

5

10. A microarray in accordance with claim 4, wherein said plurality of HLA Class I oligonucleotide probes are present on said solid support at a surface density of from about 250 to about 450 angstrom²/molecule.

10

11. A microarray in accordance with claim 4, wherein said plurality of HLA Class I oligonucleotide probes are present on said solid support at a surface density of from about 325 to about 375 angstrom²/molecule.

15

12. A method of preparing an array of covalently-attached oligonucleotide probes, said method comprising;

20

(a) contacting a solid support with an aminoalkyltrialkoxysilane in the vapor phase at reduced pressure to form an aminoalkylsilane-derivatized solid support; and

10

(b) contacting said aminoalkylsilane-derivatized solid support with a linking group to covalently attach said linking group to said aminoalkylsilane-derivatized solid support to form a linking-group modified solid support; and

25

(c) attaching a plurality of oligonucleotide probes to said linking group modified solid support to form said array of covalently-attached oligonucleotide probes.

15

30

13. A method in accordance with claim 12, wherein said contacting of step (a) is carried out at reduced pressure and with heating.

35

14. A method in accordance with claim 12, wherein said aminoalkyltrialkoxysilane is aminopropyltrimethoxysilane.

20

15. A method in accordance with claim 12, wherein said linking group is 1,4-phenylenediisothiocyanate.

40

16. A method in accordance with claim 12, wherein said plurality of oligonucleotide probes is a plurality of HLA Class I oligonucleotide probes.

45

17. A method in accordance with claim 12, wherein said plurality of oligonucleotide probes is a plurality of HLA-B oligonucleotide probes and is sufficient to represent all known polymorphisms in exons 2 and 3 of the HLA-B locus.

25

50

18. A method of HLA Class I tissue typing, said method comprising:

55

5

(a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;

10

(b) contacting said labeled, single-stranded DNA sample with a microarray prepared according to claim 12 under hybridization conditions; and

5

(c) detecting a hybridization pattern for said DNA sample and assigning an HLA Class I allele type by analysis of said hybridization pattern.

15

19. A method of HLA tissue typing, said method comprising:

(a) selectively amplifying the HLA regions in a genomic sample using asymmetric PCR and labeled primers to form a labeled, single-stranded DNA sample;

10

(b) contacting labeled, single-stranded DNA sample with a microarray prepared according to claim 12 under hybridization conditions; and

20

(c) detecting a hybridization pattern for said DNA sample and assigning an HLA allele type by analysis of said hybridization pattern.

25

20. A method of HLA-B tissue typing, said method comprising:

15

(a) amplifying exons 2 and 3 from a genomic sample of tissue using labeled primers and an asymmetric PCR method to form a labeled, single-stranded DNA sample;

30

(b) contacting said labeled, single-stranded DNA sample with the microarray of claim 4 under hybridization conditions; and

20

(c) detecting a hybridization pattern for said DNA sample and assigning an HLA-B allele type by analysis of said hybridization pattern.

35

40

45

50

55

SEQUENCE LISTING

<110> FRED HUTCHINSON CANCER RESEARCH CENTER
UNIVERSITY OF WASHINGTON

<120> OLIGONUCLEOTIDE ARRAYS FOR HIGH RESOLUTION HLA TYPING

<130> 1453FA-52-1PC

<140> PCT/US00/
<141> 2000-06-16

<150> 60/139,643
<151> 1999-06-17

<160> 141

<170> PatentIn Ver. 2.1

<210> 1
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 1
tcacaccctc cagagcatgt 20

<210> 2
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 2
tcacatcctc cagaggatgt 20

<210> 3
<211> 20
<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 3

tcacacttgg cagacgatgt

20

<210> 4

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 4

tcacaccctc cagtggatgt

20

<210> 5

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 5

tcacacttgg cagaggatgt

20

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 6

tcacaccctc cagacgatgt

20

<210> 7
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 7
tcacaccctc cagaatattg 20

<210> 8
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 8
tcacatcatc cagagcatgt 20

<210> 9
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 9
tcacaccatc cagaggatgt 20

<210> 10
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 10
tcacatcatc caggtgatgt

20

<210> 11
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, Location 5-24.

<400> 11
tcacaccctc cagaggatgt

20

<210> 12
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 12
atgtacggct gcgacgtggg

20

<210> 13
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 13
atgtatggct gcgaccctggg

20

<210> 14
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 14
atgttttggt ggcacgtggg 20

<210> 15
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 15
atgtaagggt ggcacgtggg 20

<210> 16
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 16
atgtctgggt ggcacgtggg 20

<210> 17
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 17
atgtacgggt ggcacgtggg 20

<210> 18
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 18
atgtttggct gcgacctggg 20

<210> 19
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 19
atgtatggct gcgacatggg 20

<210> 20
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 21-40.

<400> 20
atgtatggct gcgacgtggg 20

<210> 21
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 41-60.

WO 00/79006

PCT/US00/16722

<400> 21
gcccgcacggg cgcctcctcc

20

<210> 22
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 41-60.

<400> 22
gcccgcacggg cgcctcctcc

20

<210> 23
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 41-60.

<400> 23
gcccgcacggg cgcctcctcc

20

<210> 24
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 24
gcgggcctga ccagtagcc

20

<210> 25
<211> 20
<212> DNA
<213> Artificial Sequence

WO 00/79006

PCT/US00/16722

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 25

gcgggcataa ccagtagcc

20

<210> 26

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 26

gcgggcataa ccagttagcc

20

<210> 27

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 27

gcgggtataa ccagttagcc

20

<210> 28

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 28

gcgggcatga ccagtcagcc

20

<210> 29

WO 00/79006

PCT/US00/16722

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 29
gcgggtatga ccagtccgcc 20

<210> 30
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 30
gcgggtacca ccaggacgcc 20

<210> 31
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 31
gcgggcacga ccagttcgcc 20

<210> 32
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 32

WO 00/79006

PCT/US00/16722

gcgggcataa ccagttcgcc

20

<210> 33

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 33

gcgggtatga ccaggacgcc

20

<210> 34

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 34

gcgggtataa ccagttagcc

20

<210> 35

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 61-80.

<400> 35

gcgggtatga ccagtacgcc

20

<210> 36

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 51-100.

<400> 36
tacgacggca aagattacat 20

<210> 37
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 3, location 51-100.

<400> 37
tacgacggca aagattacat 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 111-130.

<400> 38
gaggacctga gctcctggac 20

<210> 39
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 111-130.

<400> 39
gaggacctgc gctcctggac 20

<210> 40
<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 40

cgccgcggac acggcggctc

20

<210> 41

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 41

cgccgcggac accgcggctc

20

<210> 42

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 42

cgccgcggac aaaggcggctc

20

<210> 43

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 43

cgccgcggac acggcagctc

20

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 44
cgccgcggac accgcggctc 20

<210> 45
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 131-150.

<400> 45
cgccgcggac accgcggctc 20

<210> 46
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 151-170.

<400> 46
agatcaccca gctcaagtgg 20

<210> 47
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA

Exon Location 151-170.

<400> 47

agatctccca gcgcaagtg

20

<210> 48

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FCR Probe HLA
Exon Location 151-170.

<400> 46

agatcaccca gcgcaagtg

20

<210> 49

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FCR Probe HLA
Exon Location 171-190.

<400> 49

gaggcgccc gtgaggcga

20

<210> 50

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: FCR Probe HLA
Exon Location 171-190.

<400> 50

gaggcgccc gtgtggcga

20

<210> 51

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 51

gcagcggaga gcctacctgg

20

<210> 52

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 52

gcaggacaga gcctacctgg

20

<210> 53

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 53

gcagtggaga gcctacctgg

20

<210> 54

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 54

gcagctgaga acctacctgg

20

<210> 55
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 55
gcagcggaga acctacctgg 20

<210> 56
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 191-210.

<400> 56
gcagctgaga gctacctgg 20

<210> 57
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 57
agggcgagtg cgtggaatgg 20

<210> 58
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 59

agggcctgtg cgtggagtgg

20

<210> 59

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 59

agggcctgtg cgtggacggg

20

<210> 60

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 60

agggcctgtg cgtggagtgg

20

<210> 61

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 61

agggcacgtg cgtggagtgg

20

<210> 62

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 62

agggcctgtg cgtggagggg

20

<210> 63

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 63

aggacctgtg cgtggagtgg

20

<210> 64

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 211-230.

<400> 64

agggcacgtg cgtggagtgu

20

<210> 65

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 65

ctccgcagaa acctggagaa

20

<210> 66
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 66
ctccgcagat acctggagaa 20

<210> 67
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 257-276.

<400> 67
ggacaagctg gagcgcgctg 20

<210> 68
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 257-276.

<400> 68
ggacacgctg gagcgcgctg 20

<210> 69
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 257-276.

<400> 69
ggagacgctg cagcgcgagg 20

<210> 70
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 1-20.

<400> 70
gtccccactt catgaggtat 20

<210> 71
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 1-20.

<400> 71
gtccccactt catgaggtat 20

<210> 72
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 72
ttctacacct ccgtgtcccg 20

<210> 73
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 73

ttctacaccg ccatgtcccg

20

<210> 74

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 74

ttcgcacaccg ccatgtcccg

20

<210> 75

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 75

ttccacacct cagtgtcccg

20

<210> 76

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 76

ttccacaccg ccatgtcccg

20

<210> 77

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 77
ttctacaccg ctatgtcccg

20

<210> 78
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 21-40.

<400> 78
ttctacaccg ccgtgtcccg

20

<210> 79
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 041-060.

<400> 79
gcccgtccgc ggggagcccc

20

<210> 80
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 041-060.

<400> 80

gcctcgccgc ggggagcccc

20

<210> 81
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 041-060.

<400> 81
gcccgccgc ggggagcccc

20

<210> 82
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 061-080.

<400> 82
gcttcacatc agtgggctac

20

<210> 83
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 061-080.

<400> 83
gcttcacac cgtgggctac

20

<210> 84
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 061-080.

<400> 84

gcttcattgc agtgggctac

20

<210> 85

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 061-080.

<400> 85

gcttcattgc agtgggctac

20

<210> 86

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Location 081-100.

<400> 86

gtggacgaca ccagttcgt

20

<210> 87

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Location 081-100.

<400> 87

gtggacgaca ccagttcgt

20

<210> 88

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Location 081-100.

<400> 88

gtggacgaca cgtgttcgt

20

<210> 89

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Location 081-100.

<400> 89

gtggacgaca cgcagttcgt

20

<210> 90

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 111-130.

<400> 90

agcgacgcca cgagtcgag

20

<210> 91

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 111-130.

<400> 91

agcgacgcca cgagtcgag

20

<210> 92
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 096-115.

<400> 92
ttcgtgcggt tcgacagcga 20

<210> 93
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 096-115.

<400> 93
ttcgtgaggt tcgacagcga 20

<210> 94
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 121-140.

<400> 94
cgagtccgag agaggagccg 20

<210> 95
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA

Exon Location 121-140.

<400> 95

cgagtcgag gatggcgccc

20

<210> 96

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 121-140.

<400> 96

cgagtcgag gacggagccc

20

<210> 97

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 121-140.

<400> 97

cgagtcgag gaaggagccg

20

<210> 98

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PR Probe HLA
Exon Location 141-160.

<400> 98

cgggcgccat ggatagaqca

20

<210> 99

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PR Probe HLA
Exon Location 141-160.

<400> 99

cgccgcgcgt gggtggagca

20

<210> 100

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PR Probe HLA
Exon Location 141-160.

<400> 100

cgccgcgcgt gcatagagca

20

<210> 101

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 161-180.

<400> 101

ggaggggccc gaattattggg

20

<210> 102

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 161-180.

<400> 102

agaggggccc gattattggg

20

<210> 103
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 161-180.

<400> 103
ggagggggccg gagcattggg 20

<210> 104
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 161-180.

<400> 104
ggagggggccg gactattggg 20

<210> 105
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 105
accggaacac acagatctac 20

<210> 106
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 106
accggaacac acagatcttc

20

<210> 107
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 107
accgggagac acagatctcc

20

<210> 108
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 108
accggaacac acagatctgc

20

<210> 109
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 109
accggaacac acagatctcc

20

<210> 110
<211> 20
<212> DNA
<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 110

accgggagac acggaacatg

20

<210> 111

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 111

accgggatac acagatctcc

20

<210> 112

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 112

accgggagac acagatctgc

20

<210> 113

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 113

accgggaçac acagaagtac

20

WO 00/79006

PCT/US00/16722

<210> 114
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 114
acgggggagac acggaacatg 20

<210> 115
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 181-200.

<400> 115
accgggagac acagatcttc 20

<210> 116
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 201-220.

<400> 116
aaggcccagg cacagactca 20

<210> 117
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon location 201-220.

<400> 117
aagaccaaca cacagactta

20

<210> 118
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR Probe HLA
Exon Location 201-220.

<400> 118
aaggcctccg cgcagactta

20

<210> 119
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR Probe HLA
Exon Location 201-220.

<400> 119
aaggccaagg cacagactta

20

<210> 120
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence:PCR Probe HLA
Exon Location 201-220.

<400> 120
aaggccaagg cacagactga

20

<210> 121
<211> 20
<212> DNA
<213> Artificial Sequence

WO 00/79006

PCT/US00/16722

<220>

<223> Description of Artificial Sequence:PCR Probe HLA
Exon Location 201-220.

<400> 121

aagcgccagg cacagactga

20

<210> 122

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence:PCR Probe HLA
Exon Location 201-220.

<400> 122

aagaccaaca cacagactga

20

<210> 123

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 123

actgaccgag agagcctgcg

20

<210> 124

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 124

acttaccgag agaacctgcg

20

<210> 125

<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 125
acttaccgag agagcctgcg

20

<210> 126
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 126
actgaccgag aggacctgcg

20

<210> 127
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 127
acttaccgag aggacctgcg

20

<210> 128
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 128

WO 00/79006

PCT/US00/16722

actgaccgag tgagcctgcg

20

<210> 129

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 129

actgaccgag tgggcctgcg

20

<210> 130

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 216-235.

<400> 130

actgaccgag agaacctgcg

20

<210> 131

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 131

ctgcgcaccg cgctccgcta

20

<210> 132

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 132
ctgcggatcg cgtccgcta

20

<210> 133
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 133
ctgcggaccc tgcctcgcta

20

<210> 134
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 134
ctgcggaacc tgcctcgcta

20

<210> 135
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 231-250.

<400> 135
ctgcggaacc tgcgcggcta

20

<210> 136
<211> 20

WO 00/79006

PCT/US00/16722

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 251-270.

<400> 136

ctacaaccag agcgaggacg

20

<210> 137

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probe HLA
Exon Location 251-270.

<400> 137

ctacaaccag agcgaggccg

20

<210> 138

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probes HLA
Exon 2.

<400> 138

gctcccaactc catgagcctat

20

<210> 139

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: PCR Probes HLA
Exon 2.

<400> 139

cggcctcgtt ctggcttctag

20

<210> 140
<211> 21
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 2.

<400> 140
acccggtttc atttcagtt g

21

<210> 141
<211> 18
<212> DNA
<213> Artificial Sequence

<220>
<223> Description of Artificial Sequence: PCR Probe HLA
Exon 2.

<400> 141
cccaactgccc ctggtacc

18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/US00/16722

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : C12Q 1/68; C12P 19/34; C12M 1/36

US CL : 435/6, 91.2 287.2; 422/68.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/6, 91.2 287.2; 422/68.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EAST DIALOG

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHEE et al. Accessing Genetic Information with High-Density DNA Arrays. Science. 25 October 1996, Vol 274, pages 610-614.	1-20
Y	US 5,800,992 A (FODOR et al.) 01 September 1998 (01.09.1999) columns 26-31.	1-20
Y, P	US 5,959,098 A (GOLDBERG et al) 28 September 1999 (09.28.1999) columns 8-9.	12-17
Y	US 5,679,773 A (HOLMES et al) 21 October 1997 (21.10.1997) see entire document.	12-17
Y	US 5,675,060 A (BENOIST et al) 07 October 1997 (07.10.1997) see columns 27-28.	1-9, 18-20

☐ Further documents are listed in the continuation of Box C. ☐ See patent family annex.

* Special categories of cited documents:	* T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
* A* document defining the general state of the art which is not considered to be of particular relevance	* X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
* E* earlier document published on or after the international filing date	* Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
* L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another document or other special reason (as specified)	* A* document member of the same patent family
* O* document referring to an oral disclosure, use, exhibition or other means	
* P* document published prior to the international filing date but later than the priority date claimed	

Date of the actual completion of the international search

31 JULY 2000

Date of mailing of the international search report

10 OCT 2000

Name and mailing address of the ISA/US
Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703) 305-3230

Authorized officer

BJ FORMAN

Telephone No. (703) 308-0196

Form PCT/ISA/210 (second sheet) (July 1998) *